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No Transformation, No Breakthrough
Cheung Hon-Yeung
Editor-in-Chief
6th April, 2013
New breakthrough 
and innovation 
normally require 
some forms of 
courage and 
imagination. I f 
people keep on 
doing the same 
thing as usual, it 
is quite unlikely 
to bring in any 
advance.
 In nature, new features and new 
dynamic of life are normally achieved 
by transformation. An insect won’t 
become an adult if it doesn’t transforms 
and come out from a cocoon. Through 
transformation, the insect can fly and 
reach a higher and further distance. 
Certainly emerging from a cocoon is 
not an easy task and it has to pay some 
prices. The whole process may be 
difficult, painful and even dangerous. 
The emergence, acceptance and 
mature of new horizon of a civilization 
of human beings is the same. It requires 
lots of efforts, time and many people’s 
participation.
 The in f luence of  pharmacy 
professionals has been up and down. 
Pharmacists, or more properly called 
chemists before the 50s, were also 
regarded as a medical doctor or the 
healer. But in the last two centuries, their 
practices have been cast into the shade 
due to the outgrowth of medical doctors 
and become a paramedical professional. 
It is true for every pharmacist in Hong 
Kong. But in recent years, some 
improvements have occurred. In 
particular, this year is a landmark for 
all Hong Kong pharmacists; it is a year 
full of many memorable events. First 
of all, it marks the 25th Anniversary 
of inauguration of the Hong Kong 
Pharmacy Conference and the 20th 
year of publication of the Hong Kong 
Pharmaceutical Journal. At the moment 
of writing this editorial, I have received an 
invitation to attend another big event, i.e. 
the inauguration ceremony of the College 
of Pharmacy Practice, which will be held 
on 22ndJune, 2013.
 Hong  Kong  Pharmaceu t i ca l 
Journal is a flagship publication of the 
Pharmaceutical Society of Hong Kong, 
the Society of Hospital Pharmacists and 
the Practising Pharmacists Association 
of Hong Kong. Although the community 
of pharmacists is relatively small 
in comparison to other healthcare 
professionals, the spirit of pharmacists 
is not small at all. Pharmacists in Hong 
Kong are always dynamic, enthusiastic, 
highly motivated and devoted. The 
launch of this journal some 20 years 
ago and its continuous presence up 
to this day is the excellent evidence 
without saying.  Hence, congratulate to 
members of the editorial board of HKPJ 
and all its contributors in the past. We 
would like to thank all of those who have 
contributed to this journal in the past. 
Without everyone’s effort, it is impossible 
to make this colorful journal realized. 
A special thank is given to our advertisers 
and particularly our regular advertisers 
for the support they have shown. Our 
advertisers, along with all subscribers 
and members of the Pharmaceutical 
Societies are important contributors 
to the financial success of this journal. 
We thank them.
 Talking about celebration, the Hong 
Kong Pharmacy Conference was found 
even earlier. This year also marks the 
Silver Jubilee of its establishment. It 
was only a month ago that the society 
under Michael Ling’s chairing held an 
enlightening, spectacular and wonderful 
annual meeting that probably never took 
place before. I believe whoever attending 
this year’s conference would agree with 
me that it was really a joyful, inspiring 
and educational meeting. In these two 
days of meeting, many talents have 
been discovered and their shows were 
really inspiring and enlightening. These 
included the opera of Musical-Pharmtom 
performed by local pharmacists, students 
and staff from both pharmacy schools, 
the music played by the PharmCare 
Orchestra, the speeches delivered by 
the keynote speakers, the workshop 
conducted by Dr. Taylor, the debate etc. 
I believe all attendants have learned a lot 
and enjoyed every item.For those who 
missed this celebration or couldn’t turn 
up, a full report and some photos of this 
big occasion can be found in p.46-47. 
I am sure you will catch a glimpse of joy 
on every participant’s face in those two 
days during the conference. 
 We are glad to receive more support 
from the staff and students from both 
pharmacy schools in Hong Kong. Upon 
the encouragement of Professor Ian CK 
Wong, they have provided us with more 
articles than ever before and it is really 
a breakthrough. In this issue, Wong 
et al explored how the aged people in 
nursing home could be effectively served 
by pharmaceutical professionals (p.11-
15) after surveying the drug wastage 
by elderly in old aged home (p.16-18). 
These two reports are indeed the shorten 
versions of a study sponsored by the 
Pharmaceutical Society of Hong Kong 
and MSD Asia last year.  We would like 
to see more sponsorships coming from 
drug companies for uses in education 
and research purposes because 
drug discovery is expensive and time 
consuming. Today, whatever substances 
claimed to be effective for the treatment 
of a health problem requires either 
proofs of specific effect like the targeted 
therapies for renal cell carcinoma (p.20-
27) or data supports from substantial 
applications and studies of a substance, 
such as the Asian Ginseng (p.33-45) or 
paracetamol for management of fever 
(p.29-31) reported in the issue.
 There are lots of other matters to 
read in this issue of HKPJ and we hope 
whoever receiving this issue enjoy the 
information provided. Of course, we 
would be most glad for any suggestions, 
comments or a helping hand!
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US: Lower Recommended Doses for Bedtime Use of 
Zolpidem Due to the Next-morning Impairment of Certain 
Activities
Date: January 10, 2013
Canada: New Labelling Information for All Botulinum Toxin 
Products
Date: January 21, 21013
On 10 January 2013, the Food and 
Drug Administration (FDA) of the US 
notified the public of new information 
about zolpidem. FDA recommended 
that the bedtime dose be lowered 
because new data showed that blood 
levels in some patients may be high 
enough the next morning to impair 
activities that required alertness, 
including driving. This announcement 
focused on zolpidem products approved 
for bedtime use.  Data showed that the 
risk for next-morning impairment was 
highest for patients taking the extended-
release forms of these drugs (Ambien 
CR and generics). Women appeared to 
be more susceptible to this risk because 
they eliminated zolpidem from their 
bodies slower than men.
 FDA therefore required the 
manufacturers of all zolpidem products 
to lower the recommended dose. The 
recommended dose of zolpidem for 
On 21 January 2013, Health Canada 
announced that in order to help prevent 
medication errors with the use of botulinum 
toxin products, all manufacturers of these 
products were requested to revise their 
product labels so as to reflect that each 
product had its own individual potency 
and as such, was not interchangeable 
with other botulinum products. The 
labelling changes were due to a risk 
evaluation of the active ingredients 
(Clostridium botulinum toxin type A and 
type B) within these products. Botulinum 
toxins were produced by different 
manufacturing processes, were obtained 
by different techniques and were derived 
from different Clostridium strains. As a 
result of these differences, these products 
could not be interchanged as these 
changes could cause unexpected side-
effects. In Hong Kong, six pharmaceutical 
products containing botulinum toxin are 
women should be lowered from 10mg 
to 5mg for immediate-release products 
(Ambien, Edluar, and Zolpimist) and 
from 12.5mg to 6.25mg for extended-
release products. Whereas for men, the 
labelling should recommend healthcare 
professionals to consider prescribing the 
lower doses (5mg for immediate-release 
products and 6.25mg for extended-
release products). 
Source: www.drugoffice.gov.hk
registered, namely Dysport for Inj 500 
Units (HK-36983), Botox for Inj 100 Units 
(HK-41906), Botox for Inj 200 Units (HK-
60427), Btxa for Inj 50 Units (HK-51582), 
Btxa for Inj 100 Units (HK-49886) and 
Siax Inj 100 Units (HK-56847). They are 
prescription medicines indicated for the 
treatment of blepharospasm, hemifacial 
spasm and strabismus.
Source: www.drugoffice.gov.hk
Singapore: Vertical Transmission of Hepatitis B Despite 
Immunoprophylaxis 
Date: December 2012
HSA updated healthcare professionals 
on several cases of vertical 
transmission of hepatitis B (HB) despite 
immunoprophylaxis with both HB 
immunoglobulin (HBIG) and HB vaccine. 
The infants were born to HB carrier 
mothers and had received a single 
dose of HBIG at birth and completed 
a three-dose regimen of HB vaccine. 
The root cause of vertical transmission 
of HB could not be ascertained in view 
of incomplete data and multi-factorial 
nature of immunoprophylaxis failure. 
Based on these reports, the rates of 
immunoprophylaxis failure from 2009 
to 2011 were estimated to be within 
the expected incidences reported 
in literature. Healthcare professionals 
were encouraged to report all cases of 
HB infection despite immunoprophylaxis 
to HSA for on-going monitoring of this 
issue. 
Source: www.hsa.gov.sg/publish
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Canada: New Statins Labeling Update on the Risk of 
Increased Blood Sugar Levels and Diabetes
Date: January 24, 2013
On 24 January 2013, Health Canada 
informed Canadians of a labelling 
update for all cholesterol-lowering 
drugs (“statins”) regarding the risk of 
increased blood sugar levels and a 
small increased risk of diabetes among 
patients already at risk for the disease. 
Based on the review of all available data, 
Health Canada concluded that the risk 
of diabetes appeared to be mainly in 
patients with pre-existing risk factors for 
diabetes, such as high levels of glucose 
or triglycerides, obesity or high blood 
pressure. Health Canada continued 
to believe the overall cardiovascular 
benefits of statin drugs in reducing blood 
cholesterol outweigh their risks. A new 
warning about the increased blood sugar 
levels and the risk of diabetes, including 
information on how to identify high-risk 
patients, had been added to the drug 
labels for the statins currently marketed 
in Canada.
 In Hong Kong, there are 239 
registered pharmaceutical products 
which belong to the class of statins. All 
are prescription medicines indicated for 
hypercholesterolemia. The Registration 
Committee of the Pharmacy and 
Poisons Board decided that the sales 
pack or package insert of the following 
pharmaceutical products should be 
updated to include the appropriate safety 
information, examples of wordings to be 
used are:
A. Statins-containing products:
“It is recommended that liver function 
tests should be performed before the 
initiation of [brand name], and thereafter 
when clinically indicated.”
 “There have been rare postmarketing 
reports of cognitive impairment 
associated with statin use. These 
cognitive issues have been reported 
for all statins. The reports are generally 
non serious and reversible upon statin 
discontinuation, with variable times to 
symptom onset (1 day to years) and 
symptom resolution (median of 3weeks).”
 “Increases in HbAlc and fasting 
serum glucose levels have been reported 
with HMG-CoA reductase inhibitors.”
B. Atorvastatin-containing products:
“Co-administration of strong 
CYP3A4inhibitors should be avoided 
if possible. In cases where co-
administration of these medicinal 
products with atorvastatin cannot 
be avoided, lower starting and 
maximum doses of atorvastatin 
should be considered and appropriate 
clinical monitoring of the patient is 
recommended.” “In patients taking 
telaprevir, concomitant use of atorvastatin 
should be avoided.” (Also applicable 
for telaprevir-containing products) 
“The dose of atorvastatin should not 
exceed 40mg daily when taking with 
boceprevir and close clinical monitoring 
is recommended.” (Also applicable for 
boceprevir -containing products)
C. Simvastatin-containing products:
“Simvastatin is contraindicated with 
strong CYP3A4 inhibitors, as well as 
gemfibrozil, ciclosporin and danazol.” 
“Do not exceed 20mg simvastatin daily 
with amiodarone.” (Also applicable 
for amiodarone-containing products) 
“Cases of myopathy/rhabdomyolysis 
have been observed for simvastatin 
co-administered with lipid-modifying 
doses (≥ 1g/day) of niacin. The dose 
of simvastatin should not exceed 20mg 
daily in patients receiving concomitant 
medication with niacin (nicotinic 
acid) ≥ 1g/day.” (Also applicable for 
niacin-containing products) “Cases of 
myopathy, including rhabdomyolysis, 
have been reported with simvastatin co 
administered with colchicine. Caution 
should be exercised when prescribing 
simvastatin with colchicine.” (Also 
applicable for colchicine-containing 
products).
D. Lovastatin-containing products:
“Lovastatin is contraindicated with strong 
CYP3A4 inhibitors.” “The combined 
use of lovastatin with gemfibrozil or 
ciclosporin should be avoided.” “The dose 
of lovastatin should not exceed 20mg 
daily in patients receiving concomitant 
medication with danazol, diltiazem, 
verapamil or dronedarone.” “The dose 
of lovastatin should not exceed 40mg 
daily in patients receiving concomitant 
medication with amiodarone.”
 “Grapefruit juice should be avoided 
inpatients taking lovastatin.”
E. Rosuvastatin-containing products:
“The concomitant use with protease 
inhibitors is not recommended.” 
 “In JUPITER study, there was a 
significantly higher frequency of diabetes 
mellitus reported in patients taking 
rosuvastatin (2.8%) versus patients 
taking placebo (2.3%). Mean HbAlc 
was significantly increased by 0.1% in 
rosuvastatin-treated patients compared 
to placebo-treated patients. The number 
of patients with a HbAlc > 6.5% at the 
end of the trial was significantly higher 
in rosuvastatin-treated versus placebo-
treated patients.”
F. Products containing HIV protease 
inhibitors:
“Co-administration of atorvastatin 
should be avoided. In cases where 
co-administration of atorvastatin 
cannot be avoided, lower starting 
and maximum doses of atorvastatin 
should be considered and appropriate 
clinical monitoring of the patient is 
recommended.”
 “Concomitant use of lovastatin 
or simvastatin is contraindicated. 
Rosuvastatin is not recommended to 
be used with protease inhibitors.” (Also 
applicable for boceprevir-containing and 
telaprevir-containing products)
Source: www.drugoffice.gov.hk
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EU / Canada / Australia: Safety Review of Diane 35 and Its 
Generics 
Date: January 31, 2013
US: Safety Review Update of Codeine Use in Children; 
New Boxed Warning and Contraindication on Use After 
Tonsillectomy and/or Adenoidectomy
Date: February 20, 2013
On 31 January 2013, EMA announced that 
the French medicines agency (ANSM) 
planned to suspend the marketing 
authorisation for Diane 35 (cyproterone 
acetate 2 mg, ethinylestradiol 35 
micrograms) and its generics for acne 
treatment in France within 3 months. 
In France, these medicines were only 
authorised for the treatment of acne. 
However, they were also authorised for 
the treatment of acne in women who 
wished to receive oral contraception, 
as well as for the treatment of other 
skin conditions, in a number of other 
Member States in the European Union 
(EU). The announcement in France 
came after a review by ANSM that Diane 
35 and its generics carried a risk of 
thromboembolism which had been well 
known for many years, and while their 
effectiveness in treating acne was only 
moderate and with alternatives available. 
Although Member States could take 
unilateral action to suspend the marketing 
authorisation of a medicine, European 
legislation required that there was a 
coordinated European approach in these 
instances. France had already indicated 
that it would ask EMA to carry out a 
European-wide review of Diane 35 and its 
generics. EMA’s PRAC would evaluate all 
evidence on the benefits and risks of these 
medicines and give a recommendation 
on whether their marketing authorisations 
should be varied, suspended or revoked, 
in the interest of all patients in the EU. 
After the meeting in February 2013, EMA 
stated it was expected that PRAC would 
adopt a recommendation at its May 2013 
meeting. 
The FDA of the US reminded healthcare 
professionals about the risks of death 
and respiratory depression of using 
codeine in children, particularly in those 
who had undergone tonsillectomy and/
or adenoidectomy for obstructive sleep 
apnoea. These children, who were 
two to five years old, had evidence of 
an inherited ability to convert codeine 
into life-threatening or fatal amounts of 
morphine in the body. On 20 February 
2013, FDA updated the public about 
labelling changes of codeine-containing 
products to address the issue.
 Healthcare professionals should 
prescribe an alternate analgesic for post-
operative pain control in children who 
were undergoing tonsillectomy and/or 
adenoidectomy. In the US, a new Boxed 
Warning would be added to the drug 
label of codeine containing products 
about the risk of codeine in postoperative 
pain management in children following 
tonsillectomy and/or adenoidectomy. 
A Contraindication would be added to 
restrict codeine from being used in this 
setting. The Warnings/Precautions, 
Paediatric Use, and Patient Counselling 
Information sections of the drug label 
would also be updated in Hong Kong, 
 Both Health Canada and the 
Therapeutic Goods Administration of 
Australia announced on 31 January and 
5 February 2013 respectively that they 
were reviewing the safety information 
on Diane-35, and would advice and 
take appropriate action as necessary. In 
Hong Kong, Diane-35 Tab (HK-43330) is 
registered by Bayer Healthcare Ltd. and 
there are nine registered generics. All 
are prescription medicines indicated for 
the treatment of acne; other registered 
indications include androgenetic 
alopecia, mild forms of hirsutism and 
contraception. The package inserts have 
included the precaution of blood clot. 
Letter to healthcare professionals was 
issued on 31 January 2013 by DH.
Source: www.drugoffice.gov.hk
there are about 360 registered codeine-
containing pharmaceutical products and 
most of them are in syrup form. Majority 
are indicated to relieve cough and a few 
are used as pain reliever. DH had not 
received any adverse event report in 
connection with the use of the products. 
A letter to healthcare professionals was 
issued on 16 August 2012 regarding this 
issue. In view of FDA’s recommendations, 
the matter will be discussed in the 
meeting of the Registration Committee of 
the Pharmacy and Poisons Board.
Source: www.drugoffice.gov.hk
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Announcement of Results of Registration Examination for 
Pharmacists
Date: March 8, 2013
Notification of Three Human Cases of H7N9 in Shanghai 
and Anhui
Date: March 31, 2013
On 8 March 2013, the Pharmacy 
and Poisons Board of Hong Kong 
announced the results of the Registration 
Examination for Pharmacists held in 
December 2012. There were 95, 83 and 
145 candidates sitting for examinations 
in “Pharmacy Legislation in Hong Kong”, 
“Pharmacy Practice” and “Pharmacology” 
respectively, with corresponding pass 
rates of 31.6 per cent, 36.1 per cent and 
23.4 per cent. Apart from meeting other 
requirements prescribed by the Board, 
any pharmacy graduate outside Hong 
Kong intending to be registered as a 
On 31st March 2013, the Centre for Health 
Protection (CHP) of the Department of 
Health received notification from the 
National Health and Family Planning 
Commission (the Commission) concerning 
three confirmed human cases of influenza 
A (H7N9). The two cases in Shanghai 
were two men aged 87 and 27, who 
passed away on March 4 and March 10 
respectively. As regards the case in Anhui, 
the 35-year-old female patient is now in 
critical condition. Laboratory tests on 
the three patients’ specimens yielded a 
positive result for H7N9. The 27-year-old 
man was a butcher while the 35-year-old 
woman had exposure history to poultry 
before the onset of symptoms. So far, no 
abnormality was detected among the 88 
close contacts of three cases. 
 Influenza A (H7) is a statutorily 
notifiable infectious disease in Hong 
Kong. CHP is maintaining close liaison 
with the Mainland health authorities to 
obtain more information on the cases. A 
spokesman for the DH urged travellers not 
to visit wet markets with live poultry in the 
affected areas, and to avoid direct contact 
with poultry, birds or their droppings. If 
contact has been made, people should 
pharmacist in Hong Kong is required to 
pass the above three subjects. The Board 
conducts its Registration Examination 
twice a year, usually in June and 
December.
Source: www.dh.gov.hk
wash their hands thoroughly with soap 
and water. 
 As of 25 April, 2013, a total of 111 
cases have been laboratory confirmed 
with avian influenza A (H7N9) in the 
Mainland, which included Zhejiang (44 
cases), Shanghai (33 cases), Jiangsu 
(24 cases), Anhui (4 cases), Henan (4 
cases), Beijing (1 case) and Shandong 
(1 case).  Locally, no confirmed human 
case of avian influenza A(H7N9) has been 
recorded so far
Source: www.dh.gov.hk
Hypertension Is Preventable and Treatable- World Health 
Day 2013 
Date: April 2, 2013
On 2 April, 2013, the Director of Health, Dr 
Constance Chan held a press conference 
to launch an upcoming public education 
campaign on hypertension led by the 
Department of Health (DH) in collaboration 
with partners in the health-care sector. The 
campaign echoes “High Blood Pressure”, 
the theme of World Health Day 2013 
chosen by the World Health Organization 
(WHO), with the aim of reducing heart 
attacks and strokes.  Locally, the Thematic 
Household Survey conducted by the 
Census and Statistics Department in the 
last five years revealed that the prevalence 
of diagnosed hypertension in Hong Kong 
has been on a rising trend from 9.3 per 
cent in 2008, to 10.3 per cent in 2009/10, 
and 11 per cent in 2011/12. However, 
many adults in Hong Kong actually do 
not realise that they have hypertension. 
Hypertension is a silent killer. Uncontrolled 
or untreated hypertension can lead to 
serious or even fatal diseases, including 
coronary heart disease, heart attack, 
heart failure, stroke, dementia, kidney 
failure, and retinal disease.  Dr Chan 
said, “Hypertension does not usually 
give rise to symptoms. Many patients 
with hypertension may not be aware of 
their disease. Therefore, it is important to 
monitor blood pressure regularly for early 
detection of hypertension. Healthy adults 
aged 18 years or above should have their 
blood pressure checked at least every two 
years.  Hypertension is preventable. The 
risk of developing high blood pressure 
can be reduced by maintaining a healthy 
lifestyle such as reducing salt (sodium) 
intake as part of a balanced diet, engaging 
in regular physical activity, maintaining 
an optimal body weight, refraining from 
smoking and drinking.
 Dr Donald Li, the President of the 
Hong Kong Academy of Medicine, said 
that hypertension is a chronic disease 
which occurs when blood pressure is 
persistently elevated. It can be controlled 
with medication, but the objective of 
treatment is to prevent complications 
and not to seek a cure. Patients need to 
continue with the treatment and lifestyle 
modifications as advised by doctors and 
attend regular medical follow up. 
Source: www.dh.gov.hk
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HK Law Undermines TCM Exhibition
WONG Albert
Modernized Chinese Medicine International Association (email: mcmia@mcmia.org)
Dear Editor,
Our own law is undermining Hong Kong’s 
only international Chinese medicine 
exhibition-conference gala event 
(ICMCM) that has been held for the 
past 11 years at the HK Convention and 
Exhibition Center.
 Ever since the full implementation 
of the HK Chinese Medicine Ordinance 
in 2010, some of ICMCM’s exhibitors 
began to abandon the exhibition because 
the Ordinance’s Clause 119 prohibits 
the sale, importation and possession 
of unregistered proprietary Chinese 
medicine (pCM中成藥). The clause 
is reasonable in a general sense but 
becomes incongruous and unreasonable 
in the context of an international 
exhibition. 
 Chinese medicine exhibitors from 
different parts of the world congregate 
annually to HK to showcase their latest 
products. Most of these exhibits are 
brought into HK solely for promotional 
purpose and they will only be registered 
later when local distributors are found to 
sell them in HK. Some of the products 
might not even be intended for sale in HK 
but to a third country or region. Hence, 
it is unreasonable for an Ordinance to 
require exhibits to be registered prior to 
exhibitions.
 The ordinance also prohibits 
local merchants from displaying their 
newly developed, but yet unregistered, 
products. Furthermore, even legitimate 
distributors who received unregistered 
product samples at the exhibitions might 
violate the law because of possession. 
 Hence the prohibition of exhibitors’ 
unregistered pCM samples amounts not 
only to a prohibition of pCM exhibitors 
to come to HK’s Chinese medicine 
trading platform but also restricts other 
international traders to use HK as a 
center to trade among themselves.
 Five years ago, long before the 
implementation of the ordinance, 
MCMIA (Modernized Chinese Medicine 
International Association) and HKTDC 
(HK Trade Development Council) 
brought this issue to the attention of the 
Department of Health (DH) to seek the 
addition of an exemption clause to the 
ordinance’s Exemption Section or to 
grant a temporary waiver of Clause 119 
in legitimate exhibition environments. 
Unfortunately, the request was rejected 
right off hand as the department claimed 
itself to be a law enforcement agency 
and not a policy maker. Last month, 
MCMIA took the issue to the Food and 
Health Bureau (FHB), expecting a 
more sympathetic and understanding 
audience. To our disappointment, the 
issue was promptly referred back to DH 
for further consultation.
 MCMIA’s proposal to FHB was very 
simple. Exhibitors will be allowed to 
bring only a small number of exhibition 
samples (≤ 6 units) of each displayed 
product into HK after their exhibition lists 
are approved by DH ahead of time. The 
samples will be restricted to be displayed 
at the designated location and time with 
the remainder samples to be brought back 
to its country of origin after the exhibition. 
All legitimate distributors or buyers who 
receive samples must leave behind 
their personal and company information 
so that the samples are traceable. The 
distribution of the unregistered product 
samples to ordinary citizens is forbidden.
 It is clear that the procedure 
proposed above protects the general 
public from exposing to unregistered 
samples. With practically no risk to the 
public, the government’s implementation 
of an unreasonable clause in an 
exhibition environment amounts to 
the inhibition of free-trade and the 
impairment of HK’s reputation as a world 
trading center.
 It took MCMIA and HKTDC a 
dozen year since 2002 to build the 
event to its current international 
prominence. ICMCM is now an 
aggregate of events and activities 
that include an international medical/
scientific professional conference, 
a trade exhibition, a whole-day 
TCM forum for the general public, 
an international graduate student 
symposium and a student TCM 
educational display. The 3-day event 
is anchored onto the exhibition. Once 
the exhibition crumbles, all the other 
activities will follow. 
 It is sad to look back at MCMIA-
HKTDC’s 12 years of hard work to build 
up ICMCM with no government support, 
only to see it meeting its potential 
demise in a couple of years, ironically, 
because of our own outdated law and 
intransigent government policy makers 
rather than losing at the hands of our 
competitions !
Sincerely,
Modernized Chinese Medicine 
International Association
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ABSTRACT
 
Various models of pharmaceutical 
services have been provided by 
pharmacists to old aged home 
residents, however, these models 
have never been summarised and 
compared.  The aim of this scoping 
exercise is to identify different kinds 
of pharmaceutical services currently 
available to the old aged home 
residents, by means of systemic 
literature review, qualitative in-depth 
interviews with service providers 
in order to understand their models 
and qualitative semi-structured 
interviews with non-pharmaceutical 
service users in an attempt to 
investigate reasons why some homes 
do not subscribe to these services. 
The results showed that none of the 
pharmaceutical services currently 
available can uproot the causes of 
medication errors, and there is a need 
to elaborate the roles of pharmacists 
in a primary care setting.
 
K e y w o r d s :  A g e d ;  E l d e r l y ; 
Pharmaceutical Services; Nursing 
Homes; Homes for the Aged; 
Hong Kong
 
 
INTRODUCTION
 
There is a rapidly growing ageing 
population in Hong Kong[1, 2] and there 
is an issue of polypharmacy among 
the elderly.[3]  According to a 5-year 
evaluation report published in 2012, 
approximately 46.4% of medication 
errors happen in the old aged homes 
(OAHs) are drug administration error.[4]
(Table 1) In order to optimise drug 
treatments among the elderly, various 
pharmaceutical services are provided to 
the elderly living in the old aged homes 
in Hong Kong. The aim of this scoping 
exercise was to identify different kinds 
of pharmaceutical services currently 
available to them and to ascertain 
opinions from pharmaceutical service 
users and non-users (i.e. those who 
are not current users of pharmaceutical 
services but may be future potential 
users).
 
 
METHODS
 
This scoping exerciseis a 3-part study 
comprises of:
 
Part 1: Systematic literature review
Aim to identify published services in the 
literature, conference materials and the 
internet (web-based sources).
 
Part 2: Qualitative in-depth interviews 
with service providers
Interviews were conducted to study the 
service nature, resources to start and 
to sustain the services; and the key 
facilitators and barriers in running the 
services.
 
Part 3: Qualitative semi-structured 
interviews
Te l e p h o n e  i n t e r v i e w s  w i t h 
pharmaceutical service users and 
non-users were also conducted to 
determine the perceptions of users on 
the pharmaceutical services including 
benefits, shortcomings, economics, 
potential improvement and long-term 
future, as well as to identify the current 
service provision gaps by comparing the 
opinions of users with non-users.
 
 All interview data was transcribed 
and analysed separately by two 
independent reviewers.
Common problems reported Percentage of recommendations among
 the 69 recommendations in 56 OAHs(%)
Drug administration procedures 46.4
Drug storage procedures 26.1
Drug disposal  7.2
Special event reporting and following-up procedures 7.2
Staff education and training on drug management 4.3
Residents’ self-purchased medicines and residents’ 8.8 
discharge medication management
The Hong Kong Accociation of Gerontology. The Project on Accreditation System for Residential Care Services for the 
Elders in Hong Kong - Five-year review report (2005-2010). Hong Kong, 2012 1-83.
Pharmacy Education & Practice
Table 1. Five-year review report of accreditation scheme for old aged homes from 2005-2010
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Figure 1. Usual practice of drug delivery model 
in old aged homes without the subscription to 
any pharmaceutical service
Register medications
Type MAR
❖
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Delegated pharmacy
Medications 
dispensed from 
institutions
OAHs
Administered to 
patients
IT support for 
administration
MDS prepacking (weekly) 
+ electronic 
documentation
Figure 2. Drug delivery model for old aged homes subscribed to the MDS service packed by 
delegated pharmacy.
Register medications
Type MAR
❖
❖
In-house pharmacy
Medications 
dispensed from 
institutions
OAHs
Administered to 
patients
In-house pharmacist MDS 
prepacking (weekly) + 
electronic documentation
Figure 3. Drug delivery model for old aged home having an in-house pharmacist
RESULTS
Part 1: Systematic literature review
 
All services identified were categorised 
into the following according to the 
patient cohorts the services serve.
There were two services serving 
the elderly living in OAHs (Old Age 
Homes) including Monitored Dosage 
System (MDS) by pharmacy,[5] 
andvisiting pharmacist service (VPS).
[6-8] Moreover, three services serving 
all elderly in Hong Kong were identified 
including pharmacy online drug enquiry 
platform,[9, 10] elderly drug counselling 
programme in a local hospital,[11] and 
drug knowledge exchange via mass 
media.[12]
 
Part 2: Qualitative in-depth interviews 
with service providers
 
The qualitative in-depth interviews 
were conducted with three main 
pharmaceutical service providers, 
namely MDS by pharmacy, in-house 
pharmacist, MDS by OAH staff. Service 
providers of in-house pharmacist and 
MDS by OAH staffwere identified through 
snowballing technique. VPS, being as 
one of the service providers, refused to 
be interviewed.
 
Drug delivery model
 
Without any pharmaceutical service, 
the usual drug delivery model is 
represented in Figure 1. Drugs would 
be dispensed from medical institutes 
(including Hospital Authority institutes, 
private sectors, such as private hospital 
and general practitioners). When the 
drugs arrive at the OAHs, healthcare 
workers would register the drugs 
manually into their in-house record, and 
they might be computer type-written by 
their clerk into medication administration 
record (MAR) for signing during the 
drug administration process.
 
 Unlike usual drug delivery model, 
MDS by pharmacy allows repacking of 
the oral solid drugs for OAHs residents. 
When the dispensed drugs arrive at the 
OAHs, they would be transported to 
the delegated pharmacy, who would 
electronically update and document the 
medications of each resident and repack 
the oral solid dosages into MDS weekly 
pack. The prepacked MDS packs would 
be transported back to the OAHs for 
drug administration to the residents. The 
whole process is monitored by a bar-
code systemand shall minimise the steps 
handled by non-medical professionals. 
(Figure 2)
 
 Similar to MDS by pharmacy, in-
house pharmacist is also responsible 
for the repacking of the drugs for OAHs 
residents. When the dispensed drugs 
arrive at the OAHs, they would be 
transported to the in-house pharmacy, 
who would electronically update and 
document the medications of each 
resident and repack the dosages into 
MDS weekly pack. The prepacked 
MDS packs would be transported 
to each floor of the OAH for drug 
administration to the residents. 
This model shall minimise the steps 
handled by non-medical professional. 
(Figure 3)
 
 However, MDS by OAH Staffdoes 
not affect the drug delivery model, but 
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Figure 5. The medicine management process adopted to Hong Kong old aged home settings.
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Figure 4. Drug delivery model for old aged homes subscribed to the MDS repacking by 
OAH staff.
the service provider supplement the 
OAHs with a centralised computerised 
system for their easy documentation 
and typing into MAR. Hardware for 
the repacking of medications into 
MDS would be supplied by the service 
provider to allow the OAH staff to do that 
by themselves. The service provider 
also offers a mobile application for the 
documentation of electronic signatures 
during drug administration process. 
(Figure 4)
 
Part 3: Qualitative semi-structured 
interviews
 
Nine non-users were interviewed. 
The understanding of the services, 
services gaps perceived and the gap 
of understanding pharmacists’ roles by 
non-users were identified. (Table 2) 
The interviews were carried out until data 
saturation is achieved.
 
 From the results, it seems that most 
of the interviewees do not perceive the 
need to have pharmacists’ input in their 
drug delivery model. Most of them only 
see the dispensing role of a pharmacist, 
and when pharmacist are not being an 
“extra pair of hand” or when the services 
require additional charges, they do not 
see the need for such “investment”. It 
is therefore important to elaborate and 
promote the roles of pharmacists in 
primary care to the general public.
 
 
DISCUSSION
 
The Medicine Management Process
 
Figure 5 illustrate the usual medicine 
management process. The process 
begins from a physician prescribing onto 
a prescription/medication record, which 
would be dispensed in the pharmacy. 
The medications would be issued and 
the OAH nurses/health-care assistants 
would store the medication away, and 
administer to the patients according to the 
instructions written on the prescriptions/
medication records.
 
 Errors could occur at any stage of 
the medication management process.
1) Prescribing error could arise during 
the prescribing process, which is sub-
divided into:
i) errors in prescribing decision, and
ii) errors in prescription writing 
process;
both could lead to the wrong 
prescribing instructions printed on the 
prescription/medical record.
2) When the prescription arrives at 
the pharmacy, dispensing error 
could occur, which could lead to the 
wrong medication being issued to the 
patient.
3) When the medications arrive at the 
OAH, their efficacy could be affected 
severely due to sub-optimal storage 
conditions.
4) When the nurse/health-care assistant 
administer the drugs to the patient, 
administration error could occur, 
which might be caused by:
i) the wrong documentation in the 
medical record (due to wrong 
prescription writing process as 
discussed) or
Responses Counts (N=9)
No perceived need 6
Financial concern 4
Doubted the usefulness of the services 3
Complicated communication cascade 3
Reluctant to change 2
Not heard of the services 1
Table 2. Reasons for non-pharmaceutical services users not subscribing to services
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Figure 6. Medication errors could be prevented by pharmacists’ involvements.
ii) failure to identify the correct 
patient/drug, which leads to the 
patient being administered the 
wrong medication.
 
 Ideally, the errors that occur at 
various stages of the medication 
management process could be 
prevented by the involvement of 
pharmacists, which is illustrated in 
Figure 6.
 
1. Pharmacist bed-side patient care
 
A pharmacist could provide clinical 
bed-side patient care on clinic days 
or clinical rounds together with the 
on-duty physician(s) and could 
prevent prescribing errors due to 
wrong prescribing decision and errors 
arise during the prescription writing 
procedures.
 
2. Pharmacist supervised MDS system
 
MDS system has been widely used 
both locally and globally.  Prior to 
the start of the dispensing process, 
pharmacist could clinically check the 
prescriptions for legibility to prevent 
errors from the prescribing processand 
oversees the dispensing process to 
ensure the correctness of the dispensed 
medications.  If the dispensing pharmacy 
locates on-site or has close collaboration 
with the OAH, all of the medications 
could also be stored at the pharmacy, 
where the storage conditions would be 
optimised and closely monitored.
 
3. Information technology monitored 
check in drug administration
 
The use of information technology is 
the global direction as that off-loads 
the checking procedures that could 
be tedious from the nurses/health-
care assistants, which minimise the 
administration errors due to human 
factors.
 
Pharmaceutical Services
 
Various pharmaceutical services 
designed to reduce medication 
errorsin Hong Kong were identified. 
In summary, all the services serving 
patients in OAHs could not uproot the 
problems of prescribing error since all 
the pharmaceutical service providers 
are not working closely enough with the 
doctors during the prescribing process. 
However, most of the services in OAHs 
could detect (but could not prevent) the 
discrepancies in the prescription writing 
process (which could lead to potential 
medication errors). Although drug 
administration is a high risk procedure in 
OAHs, only some of the services such as 
IT Supported MDS by Pharmacist, OAH 
in-house MDS, and IT supported MDS 
for OAH staff could potentially reduce it. 
In terms of storage and drug dispensing 
(i.e. re-dispensing) errors, services with 
dispensing component could reduce 
storage and administration errors by 
taking the responsibilities away from 
non-healthcare professionals.
 
 In addition, services involving re-
dispensing cannot address the problem 
of drug wastage due to duplication 
of prescription, which arise from the 
changes in medications between 
clinic visits, transitions of care and 
unsynchronised prescribing. As a result 
of the current practice, drug labels cannot 
be changed when there is a change in 
the regimen. Hence, drugs cannot be 
reused or set aside for later use. This 
could potentially lead to a significant 
economic burden on the local healthcare 
system.
 
Generalisability and limitations
 
To our knowledge, this is the first study 
identifying the pharmaceutical services 
provided to the elderly in Hong Kong 
and examining the perceptions of service 
users and non-users towards those 
services.
 
 The quality of this scoping exercise 
heavily relied on the information 
available from the literature and 
participating pharmaceutical service 
providers. In general, major limitations 
included scarce published literature 
and refusals of interview participation. 
However, triangulation was used to 
cross examine the data collected from 
multiple sources. There are also limited 
solid data available concerning the 
medication errors and effectiveness of 
the pharmaceutical services in Hong 
Kong.
 
 The generalisability of study 
results is limited by the nature of 
qualitative study design. For the 
purpose of increasing generalisability, 
interviews were stopped when there 
was a saturation of themes. Interviewer 
bias and the ‘Hawthorne effect’ might 
also be induced during the interviews 
and observations. Efforts were made to 
ensure the objectivity of the interviewers 
and reduce the bias from the ‘Hawthorne 
effect’ by explaining that their identities 
would be kept confidential.
 
Implications for practice
 
Prescriptions could be sent directly to the 
local/delegated community pharmacies 
after the process of prescribing to avoid 
the duplicated procedures of dispensing 
process of the current MDS packing 
systems. The community pharmacies 
can become a point for medication 
reconciliation when the prescriptions 
are presented. Community pharmacies 
may be contracted to specific nursing 
homes so that there is ownership for 
the roles of medication reconciliation 
and medication review. However, a 
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centralised remuneration mechanism for 
the community pharmacies is required 
to streamline reimbursement from the 
government healthcare body. Further, 
from a clinical perspective, there is a 
need for consistency with respect to the 
availability and access to patients’ full 
medical history including the patient’s 
medication records, diagnostic and 
laboratory reports which are pertinent for 
complete and thorough pharmaceutical 
care. This would require the granting of 
access to patient’s information including 
the upcoming Electronic Health Record, 
to community pharmacies.
 
 The mandatory printing of discharge 
and post-clinic summaries for every 
patient is recommended since it could 
facilitate the communications during 
the transition of care and allow the 
staff at each point of care to have a 
comprehensive profile of the care plan 
and medication record. Importantly, any 
change to the medication list needs to 
be adequately highlighted, documented 
and importantly communicated between 
health care providers. There is a need 
for more consistent procedures with the 
communication of any changes made to 
drug management at transitions of care.
 
 Pre- and post- clinic patient and 
medication record screening can 
potentially prevent prescribing errors. 
It can possibly be achieved by several 
service models, e.g. VPS, outreach 
services and in-house pharmacist in 
OAH; however, modification of current 
service may be necessary. In an ideal 
situation, the physical presence of a 
pharmacist on clinic day can prevent 
prescribing error.
 
 
RECOMMENDATIONS FOR FUTURE 
RESEARCH
 
Firstly, a monitoring surveillance 
system with OAHs, doctors and nurses 
should be developedto systematically 
record and collect data. Currently, the 
prevalence of medication incidents in 
the OAHs of Hong Kong could not be 
measured systematically due to the sub-
optimal record keeping practices among 
doctors and nurses. There is a need 
for a monitoring surveillance system 
for recording the data to measure the 
prevalence of medication incidents so 
as to offer an evidence-based view to 
reflect the condition of medication errors 
in Hong Kong.
 
 Secondly, high quality studies 
such as randomised controlled trials 
are highly recommendedto evaluate 
the effectiveness of the interventions. 
Collaboration between the OAHs, 
pharmaceutical service providers and 
academics, is of utmost importance for 
the success of future studies.
 
 Thirdly, economic studiesshould be 
conducted to evaluate the feasibility of 
the implementation of the services on a 
large scale. In light of our study, it could 
be seen that most of the interventions 
were on a small scale. Therefore, 
future research should investigate 
the monetary benefits and costs by 
measuring the cost-effectiveness of 
the interventions so as to estimate the 
feasibility of implementation of larger 
scale interventions to achieve higher 
coverage in Hong Kong.
 
 Fourthly, quantitative studies on the 
volume of drug wastage as a result of 
duplicate dispensingbased on current 
service models are highly recommended. 
The financial implications can further be 
analysed.
 
CONCLUSION
 
Various pharmaceutical services were 
identified in this scoping study. The 
natures of these pharmaceutical services 
were different and help reduced different 
medication errors. However, none of 
the available servicescan uproot the 
causes of medication errors. Insufficient 
data were available for evaluate the 
effectiveness of the services in tackling 
medication errors. Moreover, problems 
of double dispensing, the lack of 
comprehensive discharge and post-clinic 
summaries, and drug wastage were 
noted in this study. Future studies are 
warrant to evaluate the cost-effectiveness 
of the services and quantify the volume 
of drug wastage. There is also a need to 
elaborate the roles of pharmacists in a 
primary care setting.
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ABSTRACT
The extend of drug wastage among 
elderly living in old aged homes 
was never investigated.  Upon the 
completion of the previous study on 
pharmaceutical services provided to 
elderly living in old aged homes, the 
amount of drugs wasted from 3,020 
residents in one of the delegated 
pharmacies over a 4-month period 
were counted and their costs were 
calculated.  The total cost of wasted 
drugs amounted to be HKD$96,924, 
with drugs acting on the central 
nervous system contributed to the 
highest cost of HKD$26,872 (27.7%), 
followed by respiratory drugs of 
HKD$23,875 (24.6%) and alimentary 
tract & metabolism of HKD$22,965 
(23.7%).  The results showed that 
for health institutes dispensing 
prescriptions of long duration to the 
elderly could lead to considerable 
amount of drug wastage and this 
issue should be addressed.
Keywords: Aged; Elderly; Nursing 
Homes; Homes for the Aged; Hong 
Kong
INTRODUCTION
The concept of medicines waste has 
not been comprehensively studied in 
Hong Kong. However, the overseas 
experiences suggest that it can place 
considerable burden on the health 
care system through a waste of 
resources and lead to economic and 
environmental concerns.[1-5] The aim of 
this descriptive study was to quantify 
the volume and corresponding costs of 
wasted drugs in old age homes (OAHs) 
in Hong Kong.
METHODS
The audit was performed using the data 
collected in a delegated community 
pharmacy. According to Social Welfare 
Department, the population of elderly 
aged 60 or above was 2,292,190 at 
2011. Among which, there were 60,406 
living in old aged homes as of March 
2012. (Social Welfare Department, 
personal communication, December 
13, 2012) Data in 3,020 elderly patients 
such as unique patient identification 
number designated for each patient by 
the community pharmacy, trade names, 
generic names, strengths, and dosage 
forms of the drugs were collected from 
September 2012 to January 2013. Unit 
prices of the drugs were derived from 
Hospital Authority (HA) drug formulary 
in Hong Kong. Prices without listing from 
the HA drug formulary were derived from 
MIMS Hong Kong.[6]  
RESULTS
A total value of HK$96,924 consisting of 
173,790 units of oral solid preparations, 
80.86 litres of oral liquid preparations, 
500 inhaler preparations, 5.384 
kilograms of external preparations 
(including cream, gel and ointment), 
427 parenteral preparations and 2,979 
other preparations (including patch, 
sachet, drops, enema, spray and rectal 
suppository) in 3,020 residents. (Table 
1) It is estimated that 10,428,435 units 
of oral solid preparations, 4,852 litres 
of oral liquid preparations, 30,002 
inhaler preparations, 323 kilograms 
of external preparations, 25,622 
parenteral preparations and 178,757 
other preparations will require disposal 
annually for all elderly living at OAHs 
in Hong Kong. The total extrapolated 
cost was HK$5,816,017. Of the total 
discarded drugs, the prices of 258.5 
drug items could not be found in HA drug 
formulary nor MIMS Hong Kong. There 
was also approximately 1-2% of drugs 
that could not be identified so they were 
not included in the calculation. 
 The drug wastes were sorted 
in accordance with the Anatomical 
Therapeutic Chemical (ATC) classification 
system. The predominant groups of the 
cost were group N (Nervous system) with 
 No. of discarded drugs Cost (HKD)
Oral solid preparations 173,790 units $50,769
Oral liquid preparations 80,860 millilitres $7,066
Inhaler preparations 500 units $20,429
External preparations 5,384 grams $1,379
Parenteral preparations 427 units $7,718
Others 2,979 units $9,562 
(including patch, sachet, drops, enema, 
spray, suppository)
Grand Total --- $96,924
Table 1. The number of discarded drugs and the corresponding costs
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27.7%, group R (Respiratory system) 
with 24.6% and group A (Alimentary tract 
and metabolism) with 23.7%. (Table 2)
 Of the disposed drugs in group N, 
anticonvulsants and antipsychotic drugs 
were expensive and in high volumes 
which constituted 30.4% (HKD$8,167) 
and 20.5% (HKD$5,511) of the total 
cost in group N respectively. In group 
R, inhalers had high value per drug 
item which ranged from HKD$30 to 
HKD$300 and accounted for 85.6% 
(HKD$20,429) of cost in group R. In 
group A, laxatives had high volumes 
which accounted for 36.9% (HKD$8,467) 
of the cost in group A. Moreover, proton 
pump inhibitors (PPIs) were some of 
the most expensive drugs, constituted 
26.9% (HKD$6,184) of the cost in group 
A. Insulin preparations were found to 
contain 11.6% (HKD$2,653) of the cost 
in group A due to their high cost per item. 
(Table 3)
 In terms of great volumes of oral solid 
preparations, there were paracetamol 
(31,519 units), tramadol hydrochloride 
this study as health care workers in 
OAHs are responsible for ensuring 
high adherence to drugs among study 
subjects. Changes in medications 
between clinic visits, transitions of care 
and unsynchronised prescribing during 
long prescription period might account 
for the significant proportion of drug 
wastes. 
Generalisability and limitations 
To our knowledge, this is the first study 
quantifying the volumes of drug wastes 
and measuring the total cost of the 
wastes. 
 There were three major limitations 
in our study. Firstly, drug wastes due to 
death are largely inevitable. However, 
the drug wastes of dead patients were 
included in the analysis. It was due to 
the limited and incomplete records to 
identify the dead patients. Secondly, 
prices of some drugs could not be 
found in HA nor MIMS so their costs 
were not included in the result. There 
were also small quantities of drugs 
which could not be identified and were 
not included in the calculation. It could 
lead to underestimation of the total 
cost of discarded drugs. However, 
the quantities of these drugs were 
insignificant and would not greatly alter 
the result. In addition, the findings in 
this study were only extrapolated for 
the elderly living in OAHs, the amount 
of drug wastage for those living at home 
remains unknown. 
Implications for practice 
The mean prescription duration for 
public health providers is about six 
months and sometimes even up to a year 
per visit to ease the pressure resulting 
from long queues. Long prescription 
duration could lead to medicines waste 
Drugs (Nervous system) Cost (HKD)
Anticonvulsants $8,167
Antipsychotics $5,511
Narcotic drugs $2,201
Benzodiazepines $1,505
Drugs (Alimentary tract and Cost (HKD) 
metabolism
Laxatives $8,467
PPIs  $6,184
Insulin $2,653
Drugs (Respiratory system) Cost (HKD)
Inhalers $20,429
Anatomical Therapeutic Chemical classification system Cost (HKD) (%)
(A) Alimentary tract and metabolism $22,965 (23.7%)
(B) Blood and blood forming organs $5,496 (5.7%)
(C) Cardiovascular system $9,944 (10.3%)
(D) Dermatologicals $1,149 (1.2%)
(G) Genito-urinary system and sex hormones $1,328 (1.4%)
(H) Systemic hormonal preparations $1,579 (1.6%)
(J) Antiinfectives for systemic use $794 (0.8%)
(L) Antineoplastic and immunomodulating agents $496 (0.5%)
(M) Musculo-skeletal system $1,062 (1.1%)
(N) Nervous system $26,872 (27.7%)
(P) Antiparasitic products, insecticides and repellents $36 (0.04%)
(R) Respiratory system $23,875 (24.6%)
(S) Sensory organs $1,320 (1.4%)
(V) Various $0.3 (0.0003%)
Grand Total $96,924 (100%)
Drugs (Nervous system) No. of discarded drugs Cost (HKD)
Paracetamol 31,519 $1,261
Tramadol HCI 5,760 $1,464
Betahistine mesylate 2,616 $387
Drugs (Alimentary tract and metabolism) No. of discarded drugs Cost (HKD)
Senna 11,335 $1,471
Famotidine 6,594 $361
Aluminium hydroxide, magnesium hydroxide, simethicon 3,958 $394
Drugs (Respiratory system) No. of discarded drugs Cost (HKD)
Bromhexine HCI 2,744 $247
Chlorpheniramine maleate 2,580 $111
(5,760 units), and betahistine mesylate 
(2,616 units) in group N. Bromhexine 
hydrochloride (2,744 units) and 
chlorpheniramine maleate (2,580 units) 
were found to have great frequency 
for disposal in group R. Senna (11,335 
units), famotidine (6,594 units) were 
found to have great frequency in group 
A. (Table 4)
DISCUSSION
The total amount of disposed drugs, 
especially the number of oral solid 
preparations was high which create 
burden to the environment. The 
estimated cost of the drug wastes was 
also high without taking the salaries 
of dispensers and pharmacists for 
dispensing the medicines which was 
wasted eventually and the disposal 
cost of the waste into account in this 
study. 
 The medication wastes due to 
intentional and unintentional non-
adherence of medications were not 
the primary causes of drug wastes in 
Table 3. The top cost of drugs according to 
therapeutic classes for disposal
Table 2. The cost of drug wastes sorted by Anatomical Therapeutic Chemical classification 
system (ATC)
Table 4. The number of discarded drugs with great frequency for disposal and the corresponding 
costs 
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whenever there are any changes to 
treatments. The deployment of repeat 
prescriptions scheme, allowing patients 
with stable clinical conditions to obtain 
drugs on monthly basis from community 
pharmacies after the first attendance 
at health institution(s), such as hospital 
and out-patient clinics is recommended. 
It could be a much improved way in 
reducing wastes and meeting the 
on-going needs of the patients. By 
outsourcing the dispensing and supply 
of repeat prescriptions to community 
pharmacies, it could also relieve the 
heavy burden of public health care sector. 
Moreover, the community pharmacists 
can also monitor the conditions of the 
patients more frequently and provide 
them with appropriate drug advice and 
better monitoring of drug compliance. 
 There is a lack of awareness among 
elderly patients to discard the obsolete 
drugs. It is recommended that the unused 
and expired drugs should be returned to 
health care institutes for proper disposal 
in Hong Kong. It can be achieved by the 
collaboration between government and 
health care institutions to establish an 
integrated mechanism for the collection 
and disposal of drug wastes. Moreover, 
public education campaign should also 
be launched to raise the awareness on 
proper disposal of medicines waste.
 Since there is no mechanism for the 
collection and disposal of drug wastes 
in the community, there may potentially 
be inappropriate disposal methods 
among the elderly living at their homes. 
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On the other hand, elderly are also very 
likely to store large stocks of obsolete 
drugs at their homes for later use due 
to inadequate knowledge. Patient safety 
concerns may also arise from taking 
expiry drugs among them.  Further 
research on exploring the problem of 
medicines waste among the elderly 
living at homes is needed.
CONCLUSION
The scale of economic and 
environmental problems of medicines 
waste was found to be substantial. 
Wastes could be reduced if the long 
prescription duration is cut short simply 
by issuing repeated prescriptions 
instead and the supply logistics could 
be effectively managed if dispensing 
service is provided by community 
pharmacies. The establishment of an 
integrated mechanism for collection of 
drug wastes in the community should 
be encouraged. Public education 
campaign should also be launched to 
raise the awareness of proper disposal 
of medicines waste. Further research 
on exploring the problem of medicines 
waste among the elderly living at homes 
is needed.
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Figure 1. Incidence and mortality of renal cell 
carcinoma cases in Hong Kong from 1990-
2009.(4)
Overview of Targeted Therapies for Renal Cell Carcinoma
Li Yuk Shing
School of Pharmacy, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China
ABSTRACT
Before 2005, systemic treatment 
options for metastatic renal cell 
carcinoma (RCC) were limited 
to cytokine therapy. Recently, 
development of novel treatment 
selections have been possible due 
to an improved understanding of 
disease biological pathways including 
vascular endothelial growth factor 
(VEGF) and mammalian target of 
rapamycin (mTOR). Uncovering these 
novel targeted biomarkers enables 
the establishment of several targeted 
therapies available for metastatic RCC 
with an improved effi cacy and safety 
profi le. These drugs include sorafenib, 
sunitinib, pazopanib, bevacizumab 
(plus Interferon-α), temsirolimus and 
everolimus. The different adverse 
events caused by targeted therapies 
and their management strategies are 
discussed. Further research studies 
on a head-to-head comparison, 
combination therapy and therapy 
in adjuvant setting as well as novel 
agents are currently in progress and 
as a result are initiating a new era of 
RCC treatment.
Keywords: Renal cell carcinoma, 
targeted therapy, VEGF inhibitor, mTOR 
inhibitor
INTRODUCTION
Renal cell carcinoma (RCC) is 
relatively rare and among the most drug-
resistant malignancies,(1) only recently 
has impressive progress in surgical 
and systemic treatment strategies 
revolutionized the disease management 
profi le. Surgical innovation such as 
laparoscopic and robotic nephrectomy 
has minimized invasiveness so that 
maximum renal function may be 
preserved.(2) Until 2005, only a single 
treatment, high-dose interleukin-2, 
has been approved by the FDA for the 
treatment of this disease despite its 
high toxicity and low response rate.(3) 
Recently, specifi c biological targets 
essential to the pathophysiology of 
RCC such as vascular endothelial 
growth factor (VEGF) and mammalian 
target of rapamycin (mTOR) have been 
discovered. New drugs acting on those 
specifi c biological pathways have been 
emerging in the market and offer new 
therapeutic options for patients with 
metastatic RCC. RCC sets a good 
example for developing targeted therapy 
based on the discovery of biological 
tumor targets for other treatment 
resistant malignancies. Thus, biological 
targeted therapies have initiated a new 
era of oncology drug research and 
development.
Epidemiology
There were 505 newly diagnosed cases 
(314 in men and 191 in women) of 
kidney and other related urinary organ 
carcinomas in Hong Kong in 2009,(4) 
contributing to 1.94% of all malignant 
diseases. The age standardized 
incidence rate between 2000 and 2009 
was 4.38 per 100,000 person years. 
(Fig. 1) illustrates that an increasing 
trend in incidence of kidney carcinoma 
has been observed over the past two 
decades.(4) Improved imaging techniques 
and widespread use of abdominal 
imaging scans may explain the 
increasing trend in renal cell carcinomas, 
however, an increase in the number of 
people with risk factors (Table 1) must 
also be considered. Kidney cancer 
is most commonly detected after 45 
years of age, comprising nearly 90% of 
patients with RCC.(4) The male to female 
ratio is about 2:1 and thus males have 
a higher risk of developing RCC. The 
5-year overall survival rate is about 70% 
in the last decade(5) however is expected 
to improve with recent development of 
targeted therapies.
Etiology
There are several established risk 
factors for RCC including smoking, 
obesity, analgesic use and hypertension 
(Table 1).(6,12) 
 Hereditary cases of RCC account 
for 2-3 % among all RCC cases.(6) 
Approximately 35% of patients with 
Von Hippel-Lindau (VHL) disease,(13) 
which is characterized by a defect on 
both allele of the tumor suppressor VHL 
gene on chromosome 3p25-26,(14) may 
develop clear cell RCC which tend to be 
early onset and multifocal. For sporadic 
Active and passive smoking Relative risk of about 2-3 comparing with non-smokers.(7, 8)
 Smoking cessation could reduce the risk of RCC with 20%-30% after   
 cessation for 10-15 years and 50% if quit for more than 30 years.(9)
Obesity Body Mass Index>25 kg/m2: Relative risk of 1.5-2.5 comparing with 
 normal weight (10)
Prolonged poorly controlled  Diastolic Blood Pressure (>90 mmHg): Relative risk of 2 comparing with  
hypertension(11) normal diastolic Blood Pressure (<70 mmHg)
 Systolic Blood Pressure(>150 mmHg): Relative risk of 1.6 comparing with  
 normal systolic Blood Pressure (<120 mmHg)
Long term analgesic use(12) Acetaminophen: 33% increase in risk
 Non-Steroidal Anti-Infl ammatory Drug: 26% increase in risk 
Drugs & Therapeutics
Table 1.  Risk factors for RCC
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pVHL
h.p.
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Figure 2. (A) Under normal pVHL, HIFα degrades with pVHL binding through ubiquitin 
attachment in proteasome. (B) Under impaired pVHL condition, accumulation of HIFα leads to 
overexpression of hypoxia inducible genes. [Modified from Rini & Small](19)
RCC cases, clear cell RCC patients 
would acquire inactivation in both VHL 
alleles, leading to destruction of tumor 
suppressing VHL protein. Thus sporadic 
clear cell RCC tends to be late in onset 
and unifocal.
Classification
Despite its predominance, clear cell 
RCC is not the only kidney carcinoma 
subtype present. It accounts for 75% 
among all RCC cases. Other named 
subtypes(15) include papillary type I (5%), 
papillary type II (10%), chromophobe 
(5%), oncocytoma (5%), and also rare 
but aggressive subtype collecting duct 
carcinoma (<1%). Those subtypes 
differ in histopathologic and cytogenetic 
features eg. clear cell RCC subtype is 
characterized with cystic architecture, 
clear cytoplasm as well as chromosome 
3p loss.(15) Also they may vary in prognosis 
and aggressiveness. For example, renal 
oncocytoma subtype has excellent 
prognosis and is relatively benign and 
rarely metastatic,(16) but collecting duct 
carcinoma is very aggressive.
Pathology 
Von Hippel-Lindau (VHL) tumor-
suppressor gene undergoes inherited 
or sporadic inactivation in at least 
60% of these tumors.(17) The defective 
gene fails to produce VHL protein, 
which is an important regulator of 
hypoxia inducible factor (HIF). HIF is 
degraded upon VHL protein binding 
through polyubiquitination and hence 
proteasome degradation in condition 
of abundant oxygen supplies.(18) HIF is 
a heterodimeric protein transcription 
factor of over 100 genes that promotes 
adaptation and survival under hypoxic 
conditions.(19) However, HIF upregulates 
with normal oxygen supply since failure 
in degradation by proteasome through 
binding with VHL protein. Thus hypoxia 
inducible proteins, including vascular 
endothelial growth factor (VEGF), 
platelet derived growth factor (PDGF), 
transforming growth factor α (TGF-α) etc, 
that promote angiogenesis and tumor 
development are overexpressed and 
hence renal cell carcinoma may develop 
(Fig. 2).(17,19) Also, mammalian target 
of rapamycin (mTOR) is another key 
inducing factor in development of RCC. 
Since activation of mTOR is associated 
with upregulation of HIF and mTOR 
regulates protein translation, mTOR 
may also predispose RCC.(17) Improved 
knowledge in molecular biology and 
pathway of RCC enables development 
of novel therapeutic targeted therapies. 
Recent research(20) in TNF receptor-
associated factors shows that it may 
have a role in apoptosis of RCC and is 
currently under study.
Clinical presentations and diagnosis
Widespread use of imaging modalities 
such as computed tomography (CT) 
scans contributes to early incidental 
detection of renal masses during 
radiographic imaging of neighbouring 
organs. Those incidentally diagnosed 
renal masses are usually smaller in size 
and more localized as compared with 
those patients with symptoms such as 
the classic triads of flank pain, hematuria, 
and palpable abdominal mass present 
in less than 10% of RCC patients.(21) 
Other systemic symptoms(6, 21) include 
bone pain, fatigue, weight loss, anemia, 
hypertension, fever, hypercalcaemia 
and lower extremity edema which may 
be due to metastatic growth in other 
organs. Complete Blood Count (CBC), 
comprehensive metabolic panel, including 
LDH, urinalysis and also CT or MRI 
imaging of chest, abdomen and pelvis is 
required as initial workup to characterize 
the renal tumor and determine staging 
and prognosis factors when suspicious 
masses are discovered.(22)
Staging and Prognosis
Staging of RCC was introduced by the 
American Joint Committee on Cancer 
(AJCC) and was recently updated in 
2010.(23) The staging classification mainly 
encompasses the extent of tumor (T), 
involvement of lymph node (N) and 
presence of metastases (M). For AJCC 
staging (Table 2), estimated average 
5 year survival rates in RCC(24) is 96% 
for stage I, 82% for stage II, 64% for 
stage III and 23% for stage IV.
 Primary Tumor (T) Regional Lymph Nodes (N)
 Involvement Extent of disease NX Regional lymph nodes cannot 
    be assessed
TX Primary tumor cannot  N0 No regional lymph node 
 be assessed   metastasis
T0 No evidence of primary tumor  N1 Metastasis in a single regional  
 lymph node(s)
T1a Tumor ≤ 4 cm limited to kidney  Distant Metastasis (M)
T1b Tumor ≥ 4 cm to ≤ 7 cm  M0 No Distant Metastasis
T2a Tumor >7cm to ≤ 10cm  M1 Distant Metastasis
T2b Tumor > 10 cm   Staging
T3a Into renal vein or its  not beyond Stage I T1 N0 M0 
 segmental branches Gerota’s fascia  
T3b into vena cava below the diaphragm Stage II T2 N0 M0
T3c Into vena cava  or invades  above the diaphragm Stage III T1 or T2 N1 M0 
 wall of vena cava
T4 invades beyond Including contiguous   T3 N0 or N1 M0 
 Gerota’s fascia extension into the  Stage IV T4 Any N M0 
  ipsilateral adrenal gland  Any T Any N M1
Table 2.  AJCC TNM Staging System for kidney cancer. [Adapted from Edge, et al](23)
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For metastatic RCC patients, the 
Memorial Sloan-Kettering Cancer Center 
(MSKCC) model (Table 3)(25) is commonly 
used to determine prognosis of patients. 
Low risk was defined as presence of 
none or one risk factor, intermediate 
risk as two risk factors, and high risk 
or poor prognosis as three or more risk 
factors. Corresponding two year overall 
survival rate for low, intermediate and 
high risk groups were 75%, 53%, and 7% 
respectively.(26)
Treatment
For local RCC (stage I to III), open, 
laparoscopic, or robotic surgical excision 
is the primary method of disease 
control.(22) In patients with advanced or 
metastatic disease (stage IV), systemic 
treatment options following cytoreductive 
nephrectomy are immunotherapies 
including high dose interleukin-2 or 
Interferon-alpha and more recently 
targeted therapies (Table 4).(22)  Six 
new drugs for metastatic RCC have 
been approved in Hong Kong either as 
first or second line therapy: sunitinib, 
sorafenib, pazopanib, bevacizumab 
(with Interferon-α), temsirolimus and 
everolimus. Axitinib,(28) a novel drug 
approved recently by FDA in US in 2012, 
is also indicated for metastatic RCC after 
failure of one prior systemic therapy. 
Enrolling in clinical trial is also another 
treatment option for RCC patients. 
Immunotherapy
Prior to emergence of targeted therapies 
the only systemic therapies available 
against metastatic RCC were high dose 
bolus IL-2 or IFN-α. With both IFN-α and 
IL-2, objective response rate (ORR) was 
reported to be between 9.9%-23.2%.(29-31) 
No direct comparison of high dose bolus 
IL-2 or IFN-α has been performed. 
National Comprehensive Cancer Network 
(NCCN) guidelines include high dose 
IL-2 as a category 2A recommendation 
for selected patients with excellent organ 
function and no comorbidities.(22) Also, 
clear cell histology, carbonic anhydrase-9, 
and favorable score on MSKCC and 
University of California Los Angeles 
(UCLA) Survival After Nephrectomy and 
Immunotherapy (SANI) scale may be 
predicted as benefiting from cytokine 
therapy.(32) However, interleukin-2 use 
has markedly declined(33) since currently 
available targeted therapies show an 
improved benefit in both efficacy and 
safety. IFN-α is rarely used as a single 
agent in metastatic RCC, but it is usually 
used in combination with bevacizumab 
in a regimen that has shown better 
progression-free survival (PFS) than 
IFN-α alone.(34) One study(35) suggested 
that patients receiving high dose IL-2 
after VEGF therapy experienced lack of 
antitumor activity as well as high rate of 
severe cardiac toxicities (40%).
Targeted therapies
The six biological targeted therapies 
available in Hong Kong are all for 
palliative treatment of either treatment-
naïve or previously-treated RCC. Table 
5 summarizes the recommendation by 
guidelines of different authorities and 
key efficacy data from pivot clinical trials 
of the targeted therapies.(22, 36-49) Table 
6 summarizes the dose, route, dose 
adjustment, drug interaction and adverse 
event (AE) profiles of different targeted 
therapies. Moreover, Fig. 3 shows the 
specific therapeutic targets for different 
targeted therapies of metastatic RCC. 
Tyrosine Kinase Inhibitors (TKI)
Sorafenib, sunitinib and pazopanib 
are multikinase inhibitors indicated for 
metastatic renal cell carcinoma. They 
have similar mechanism of actions, 
blocking tumor angiogenesis by inhibiting 
multiple receptor tyrosine kinases such 
as vascular endothelial growth factor 
receptor (VEGFR), platelet derived 
growth factor receptor (PDGFR), cytokine 
receptor (c-KIT), fms-like tyrosine-kinase 
3 (FlT3). 
 All of these drugs are available 
in oral form and whilst Sorafenib and 
sunitinib can be taken with or without 
food. Pazopanib should be taken one 
hour before or two hours after meals 
since absorption and therefore systemic 
exposure of pazopanib increases 
with food.(53) Moreover, TKIs are all 
CYP3A4 substrates and therefore 
pharmacists should be aware of those 
drug interactions between TKIs and 
both CYP3A4 inducers and inhibitors. 
Pharmacists should advise on dose 
adjustments in the event of any potential 
drug interaction. In addition, both the 
herbal preparation St. John’s Wort and 
grapefruit juice are common CYP3A4 
inducers and inhibitors respectively and 
RCC patients taking TKI medications 
should be counselled appropriately.
 Hypertension is a frequent adverse 
event associated with TKIs and must 
be carefully monitored and managed.(56) 
Cardiac toxicity such as heart failure, 
QT wave prolongation and an increased 
risk of bleeding due to inhibition of VEGF 
which has a role in maintaining vascular 
structure of endothelial cell has also been 
associated with TKIs. Hepatotoxicity is 
another serious adverse event associated 
with the administration of sunitinib and 
pazopanib and the FDA has added a 
black box warning to their labels.
 Other common adverse events 
include dermatological AEs (hand 
foot skin reaction), gastrointestinal 
AEs (diarrhoea, vomiting), fatigue and 
headache (Table 5).
Sorafenib
Sorafenib was the first oral multi-kinase 
inhibitor to be approved by US FDA in 
2005 for the treatment of patients with 
metastatic RCC and it is recommended 
as second-line therapy after cytokine 
therapy failure.(50)  As described in Table 
MSKCC Prognostic Factors
Karnofsky Performance Score (KPS) ≤ 70
≥2 sites of organ metastasis
Interval of less than a year from original diagnosis to the start of systemic therapy
Corrected serum calcium level > 10 mg/dl (2.5 mmol/L)
Hemoglobin level < lower normal limit(<13 g/dL for men and <11.5g/dL for women)
Lactate dehydrogenase level > 1.5 times upper normal limit (300U/L)
Stage Treatment Options
Ia Partial Nephrectomy(Preferred) 
 Radical nephrectomy(If partial not feasible or tumor in centralized location) 
 Active surveillance 
 Thermal ablation therapy for non-surgical candidates
Ib Partial Nephrectomy 
 Radical Nephrectomy
II, III Radical Nephrectomy
IV (Cytoreductive) nephrectomy + Possible surgical metastasectomy 
 Systemic therapy (Immunotherapy or targeted therapy) 
 Clinical Trial
Table 3. MSKCC prognostic factors(27)
Table 4. Treatment options of clear cell Renal Cell Carcinoma(22)
HKPJ   VOL 20  NO 1   Jan-Mar 2013
22
HKPJ   VOL 20  NO 1   Jan-Mar 2013
23
VEGFR 
and 
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5, its approval was based on a pivotal 
phase III randomized, double blinded 
and placebo-controlled TARGET trial in 
which 903 cytokine-refractory patients 
were studied.(37) The result of this 
study showed a significant superiority 
in Progress-Free Survival (PFS) and 
Objective Response Rate (ORR) but no 
benefit for Overall Survival (OS).(37,38)  It 
has been suggested that if patients in the 
placebo arm of this study were switched 
to the sorafenib arm, then there would 
be an improvement in overall survival 
(17.8 months vs 14.3 months, p=0.03).(38) 
The safety profile of sorafenib was 
generally good and the drug was well 
tolerated. Sorafenib was moved towards 
second-line therapy after market launch 
of sunitinib, another multikinase inhibitor 
with superiority efficacy.(22)
Sunitinib 
Sunitinib is another oral multi-kinase 
inhibitor that was approved by the FDA 
in 2007. It was administered(50) in a 
6-week cycle and the clinical trial that 
encouraged this registration was a phase 
III study that compared sunitinib with 
IFN-α in 750 treatment-naïve patients.(39) 
Sunitinib demonstrated a significant 
improvement in PFS, ORR and OS rate 
and an overall benefit over IFN-α alone 
with a comparatively increase in adverse 
events. The adverse events such as 
hand-foot skin reaction, hypertension 
and gastrointestinal toxicity caused 
by sunitinib were similar to sorafenib 
but appeared more frequently.(39) 
Additional severe adverse events other 
than those experienced with sorafenib 
namely, hepatotoxicity (<1%), cardiac 
toxicity(<1%) and hypothyroidism 
(9.7%)(50) have been observed with the 
use of sunitinib and therefore related 
routine laboratory biochemical testing 
and monitoring the signs of congestive 
heart failure should be implemented as 
standard practice. Due to its acceptable 
toxicity as well as its promising result in 
first-line RCC treatment study, it has been 
recommended by NCCN and EAU(22, 36) 
as first-line therapy in treatment-naïve 
patients.
Pazopanib
Pazopanib is the latest multi-kinase 
inhibitor approved by FDA in 2009. The 
clinical trial(45) pivotal in the acceptance 
of this drug into RCC treatment was a 
randomized, double-blinded, placebo-
controlled phase III study of 435 either 
treatment-naïve or cytokine-pretreated 
patients with metastatic RCC. Pazopanib 
showed a significant difference in 
PFS and ORR compared to placebo 
regardless of MSKCC risk score, age, sex 
or Eastern Cooperative Oncology Group 
(ECOG) performance status.(45) However, 
pazopanib does not show an overall 
survival (OS) advantage.(46) It appears 
Drug Name Class NCCN  EAU Patient Compare Median PFS vs ORR vs OS vs 
  Guidelines(20) Guidelines(35) Population against compar-ator compa-rator comparator
      (months)  (months)
Sorafenib(36, 37)  First-line for selected  Second line Progressed Placebo 5.5 vs 2.8 10% vs 2% 17.8 vs 15.2
  patients (Cat 2A) following Disease  p<0.001 p<0.001 p=.146 
  and cytokines after 1  HR= 0.44  HR=0.88 
  Second-line following   systemic 
  cytokine therapy  therapy 
  (Cat 1) and  following  
  other TKIs (Cat 2A)
Sunitinib(38, 39)  First-line (Cat 1) First-line for low No prior IFN-α 11 vs 5 47% vs 12% 26.4 vs 21.8
  and or immediate systemic  p<0.001 p<0.001 p=.051 
  Second-line following  risk therapy  HR=0.42  HR=0.821 
  cytokine therapy  
  (Cat 1) and  following 
  other TKIs (Cat 2A)
Bevacizumab+  First-line (Cat 1) First-line for low No prior A IFN-α 10.2 vs 5.4 31% vs 13% 23.3 vs 21.3 
IFN-α(40-43)  and or immediate systemic + p=0.001 p=0.001 p=.1291
  Second-line following  risk therapy Placebo HR=0.63  HR=0.86 
  cytokine therapy   B IFN-α 8.5 vs 5.2 25.5% vs 13.1% 18.3 vs 17.4 
  (Cat 2A) and  following     p<0.001 p<0.001 p=.069
  other TKIs (Cat 2B)    HR=0.71  HR=0.86
Pazopanib(44, 45)  First-line (Cat 1) First-line for low With or without Placebo 9.2 vs 4.2 30% vs 3% 22.9 vs 20.5
  and or immediate prior cytokine  p<0.001 p<0.001 p=.224
  Second-line following  risk therapy  HR=0.46  HR=0.91 
  cytokine therapy  Second line
  (Cat 1) and  following  following 
  other TKIs (Cat 3) cytokines
Temsirolimus(46)  First-line for poor First-line for No prior IFN-α 3.8 vs 1.9 8.6% vs 4.8% 10.9 vs 7.3
  prognosis patients  high risk systemic   p<0.01 p=.008 
  (Cat 1) and  therapy    HR=0.73 
  Second-line following  Poor-prognosis 
  cytokine therapy  
  (Cat 2A) and 
  following other TKIs  
  (Cat 2B)
Everolimus(47)  Second-line following  Second line Prior Placebo 4.9 vs 1.9 1.8% vs 0% 14.8 vs 14.4
  TKI (Cat 1) following VEGFR TKI  p<0.001  p=.162
   VEGFR TKI therapy  HR=0.33  HR=0.87
Axitinib VEGFR N/A N/A Prior systemic Sorafenib 6.7 vs 4.7 19% vs 9% Not yet
(yet approved  inhibitor   therapy  p<0.0001  released 
in HK)(48)      HR=0.665
Note: ORR= Objective Response Rate, PFS= Progression Free Survival, OS=Overall Survival, HR=Hazard Ratio, VEGFR= Vascular Endothelial Growth Factor Receptor, PDGFR= Platelet-
Derived Growth Factor Receptor, mTOR= Mammalian Target of Rapamycin, TKI= Tyrosine Kinase Inhibitor NCCN categories.(20) 
Cat 1=Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate 
Cat 2A=Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate 
Cat 2B=Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate 
Cat 3=Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate
mTOR 
inhibitor
Table 5.  Summaries of National Cancer Comprehensive Network® (NCCN) and European Association of Urology (EAU) guideline recommendation and 
pivotal clinical trials of the six approved targeted therapies plus axitinib(22, 36-49)
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Protein translation
Angiogenesis
Bevacizumab
Axitinib
Sunitinib
Pazopanib
Sorafenib
Everolimus
Ternsirolimus
Sirolimus
Figure 3. Therapeutic targets in renal cell carcinoma. Abbreviations: VHL, von Hippel-Lindau 
protein; HIF, hypoxia-induced factor; TGF-α, transforming growth factor α; mTOR, mammalian 
target of rapamycin; VEGF, vascular endothelial growth factor; PDGFβ, platelet-derived growth 
factorβ; EGFR epidermal growth factor receptor; PTEN, phosphatase and tensin homologue; 
TSC1 and TSC2 tuberous sclerosis complex 1 and 2, FKBP12 FK506-binding protein 12 kD; 
elF4E eukaryotic translation initiation factor 4E; S6K, S6 kinase. [Modified from Brugarolas](17)
to have similar but lower frequency 
of AEs  compared with sorafenib and 
sunitinib from clinical trial result.(45) More 
comprehensive and extensive safety 
profile study on pazopanib is required to 
establish its safety profile since different 
AEs or increased frequency of AEs may 
possibly appear with prolonged drug 
experience. Also, a lower frequency 
of common AEs does not necessarily 
mean a lower risk of serious AEs 
requiring intervention or discontinuation. 
Pazopanib is also recommended by the 
NCCN and EAU(22,36) as first-line therapy 
in treatment-naïve patients due to its 
promising efficacy in PFS and ORR with 
a well-tolerated safety profile.
Anti-VEGF Monoclonal Antibody - 
Bevacizumab + IFN-α
Bevacizumab is an I.V. administered 
humanized monoclonal antibody and is 
given in combination with subcutaneous 
injected IFN-α. This combination was 
approved by the FDA in 2009 for 
first-line treatment of patients with 
metastatic RCC. Bevacizumab(50) binds 
to circulating VEGF and inhibits its action 
upon VEGF receptors, thus blocking the 
process of angiogenesis. Two clinical 
trials helped establish bevacizumab as 
a useful agent in RCC, these comprised 
of a randomized, double blinded phase 
III AVOREN study of bevacizumab plus 
IFN-α versus placebo plus IFN-α and 
a randomized, open-labelled phase III 
CALGB study of bevacizumab plus IFN-α 
versus IFN-α. In both trials, bevacizumab 
plus IFN-α showed superiority in PFS and 
ORR versus comparator and had a trend 
of longer OS but no significant difference 
was shown. The combination is also 
recommended by NCCN and EAU(22, 36) 
as first-line therapy of metastatic RCC. 
Name
Sorafenib
Sunitinib
Pazopanib
Bevacizumab 
+ IFN-α
Temsirolimus
Everolimus
Route
Oral
Oral
Oral
I.V. + SC
I.V.
Oral
Dose
400mg BD
50mg QD, 
4 weeks on 
followed by 2 
weeks off in a 
6-week cycle
800mg QD 
without food
10mg/kg every 
2 weeks
25 mg IV 
infusion once a 
week
10mg QD
Dose adjustment
Renal
No
No
No
No
No
No
Hepatic
No
No
200mg QD 
(moderate 
impairment)
No 
mild:  
↓to 15mg 
bilirubin>1.5x
ULN=contrain
dicated
moderate:  
↓to 5mg
Drug Interaction
CYP3A4 
inducers (↓), 
neomycin (↓)
CYP3A4 
inducers (↓), 
CYP3A4 
inhibitors (↑)
CYP3A4 
inducers (↓), 
CYP3A4 
inhibitors (↑)
No 
CYP3A4 
inducers (↓), 
CYP3A4 
inhibitors (↑)
CYP3A4 
inducers (↓), 
CYP3A4/Pgp 
inhibitors (↑)
Common Adverse Event
Dermatologic (rash, hand-foot skin reaction, 
alopecia), GI(constipation, diarrhea, 
nausea, vomiting), hypertension, fatigue, 
headache
Dermatologic (rash, hand-foot skin reaction, 
alopecia, skin discoloration), GI(diarrhea, 
nausea, stomatitis. vomiting),  dyspnea, 
fever, peripheral edema, extremity pain, 
hypothyroidism, anorexia, anemia, 
hypertension, fatigue, headache
Dermatologic (rash, hand-foot skin reaction, 
hair color changes), GI (diarrhea, nausea, 
vomiting), fatigue, hypertension, anorexia, 
headache, ALT/AST increase
Dermatologic (dry skin, skin discoloration), 
GI ( constipation, diarrhea, nausea, 
vomiting), epistaxis, hypertension, fatigue, 
headache, neutropenia, rhinitis, back pain
Dermatologic ( Rash, pruritus, acne, 
nail disorder), GI (Diarrhea, mucositis, 
vomiting, nausea), infections, edema, 
asthenia, dyspnea, cough, hyperglycemia, 
hyperlipidemia
Dermatologic ( Rash, pruritus, dry skin, nail 
disorder), GI (Diarrhea, stomatitis, vomiting, 
nausea), fatigue, edema, infections, 
cough, dyspnea,epistaxis, hyperglycemia, 
hyperlipidemia
Serious Adverse Event  
that may need intervention or 
discontinuation
Cardiac ischemia, Bleeding, GI 
perforation, QT prolongation
Hepatotoxicity, Cardiac toxicity, 
Bleeding, GI perforation, 
Hypothyroidism
Hepatotoxicity, QT 
prolongation, Bleeding, 
arterial thromboembolism, GI 
perforation, Hypothyroidism, 
proteinuria
GI perforation, Wound healing 
complications, Bleeding, 
Arterial thromboembolism, 
Reversible posterior 
leukoencephalopathy 
syndrome, proteinuria
Infusion reactions, neutropenia, 
thrombocytopenia , infections, 
GI perforation, renal failure, 
intracerebral bleeding
Non-infectious pneumonitis, 
infections,
neutropenia, thrombocytopenia, 
renal failure
Table 6. Summary of route, dose, dosage adjustment, drug interaction and adverse event profiles of different targeted therapy for metastatic renal cell 
carcinoma.(50-55)
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 Proteinuria (7%), wound healing 
p rob lems(1%) ,  gas t ro in tes t i na l 
perforation(1%) and cardiovascular 
events(1%) are all possible life 
threatening side effects of bevacizumab 
which need monitoring and prompt 
management should they arise. 
Other common side effects include 
gastrointestinal AEs(constipation, 
diarrhoea), fatigue and headache 
(Table 5).
 Moreover, pharmacists may need 
to monitor the compliance of this 
treatment which currently necessitates 
a combination of IFN-α injected 
subcutaneously three times a week 
and bevacizumab which is injected 
intravenously every 2 weeks. Phone 
calls or an injection calendar may help 
to remind patients to adapt to injection 
scheme with good compliance in an 
outpatient setting.
Mammalian target of rapamycin (mTOR) 
inhibitors
Temsirolimus and everolimus are 
mTOR inhibitors indicated as alternative 
treatment options of metastatic RCC. 
They have similar mechanism of action 
to achieve treatment target,(54, 55) binding 
to an intracellular protein FKBP-12 
and the protein-drug complex inhibits 
mTOR which controls protein translation. 
They down-regulate the activity of S6 
ribosomal protein kinase (S6K1) and 
eukaryotic elongation factor 4E-binding 
protein (4E-BP1), which are involved in 
protein synthesis. Also, mTOR inhibition 
leads to the inhibition of hypoxia-
inducing factor α (HIF-α) and thus VEGF, 
leading to anti-angiogenesis effect. Both 
mTOR inhibitors are CYP3A4 substrates. 
Thus drug-drug/drug-herb/drug-food 
interactions with mTOR inhibitors may 
occur and those drugs affecting CYP3A4 
enzymes should be avoided.
 Due to their immunosuppressive 
properties, mTOR inhibitors are 
associated with drug-induced infections 
such as urinary tract infections, 
pneumonia and reactivation of hepatitis 
B, etc. Non-infectious pneumonitis(57) is 
another class effect of mTOR inhibitors 
in which more than one quarter of 
RCC patients’ treatment with mTOR 
inhibitors had pneumonitis. Metabolism 
disorders such as hyperlipidemia and 
hyperglycemia are specific effects of 
mTOR inhibitors which pharmacists need 
to aware of and routine lab monitoring 
is required. Other common side effects 
include fatigue, asthenia, rash and cough 
(Table 5). Moreover, live vaccination 
and close contact with those who have 
received live vaccines should be avoided 
for patients treated with mTOR inhibitors.
Temsirolimus
Temsirolimus(54) is an mTOR inhibitor 
administered through 30-60 minute I.V. 
infusion once weekly and was approved 
by the FDA in 2007 for first line treatment 
of metastatic RCC patients with at least 
three of six prognostic risk factors in 
MSKCC criteria (Table 2). One major 
trial(47) was a randomized phase III study 
of 626 patients with a poor prognosis. 
Temsirolimus showed significant benefits 
in PFS, ORR as well as OS compared to 
IFN-α. The results of this trial supported 
the use of temsirolimus in the treatment 
of metastatic RCC patients with a poor 
prognosis and thus it is recommended 
by both NCCN and EAU(22,36) for this 
indication. 
 Since temsirolimus is administered 
via IV infusion, pharmacists should be 
aware of possible hypersensitivity and 
infusion site reactions and if required 
antihistamine prophylaxis should be given 
before infusion. Moreover, temsirolimus 
should be withheld if grade 3 or 
above neutropenia or thrombocytopenia 
occurred and restarted with a lower 
dose. Temsirolimus should be stored in a 
refrigerator between 2-8ºC and protected 
from light.(54)
Everolimus
Everolimus is an oral form mTOR 
inhibitor approved by the FDA in 2009 for 
second-line therapy of metastatic RCC 
after failure of TKI therapy. The pivotal 
clinical trial in the adoption of this drug 
into clinical use(48) was a randomized, 
double-blinded, placebo-controlled phase 
III study of 416 metastatic RCC 
patients with prior failure of VEGF 
therapy. Everolimus showed significant 
improvements in PFS and ORR, but 
no OS significant difference against 
placebo. Thus, NCCN and EAU(22, 36) 
recommend its use for second-line 
therapy of metastatic RCC after failure of 
systemic therapy. Everolimus should be 
protected from light and moisture in order 
to prevent reduced efficacy,(55) Monitoring 
signs of infections and lab result should 
be done routinely to minimize risk of life 
threatening adverse events.
Adverse Events Management 
Strategies
Dermatologic toxicities
Dermatologic AEs frequently appear in 
targeted therapies for RCC including 
rash, hand-foot skin reaction (HFSR), 
alopecia and pruritus. HFSR may not 
be life threatening but a dose reduction 
may be required as symptoms progress 
and affect the daily activities of patients. 
Prevention strategies such as pedicure 
before treatment may be effective in 
reducing risk and the severity of HSFR 
in patients with plantar hyperkeratosis.(58) 
Pharmacists may also counsel patients 
to reduce exposure of extremities to hot 
water, to avoid excess rubbing and not 
wear constrictive clothing. Similarly to 
wear shoes with padded insoles and use 
emollients such as moisturizing cream 
which should be applied to the hands 
and feet. For the treatment of rash, 
topical emollients, topical corticosteroids 
(short-term) and antihistamines may be 
used to relieve symptoms. Also, mild, 
non-deodorant soaps may be used and 
hot showers should be avoided.
Gastrointestinal toxicities
Patients under targeted therapies for 
RCC may experience some of the 
gastrointestinal adverse events such 
as diarrhoea, constipation, stomatitis, 
vomiting and nausea. Educating 
patients about the likelihood of these 
events is a major step in managing any 
gastrointestinal adverse events which 
would be elucidated below.(32) 
 To manage diarrhoea, patients 
should be educated to avoid foods that 
may aggravate diarrhoea such as dietary 
fibre and favour foods that may slow 
gastrointestinal motility such as banana 
and toast, etc. Also, rehydration after 
an episode of diarrhoea is essential 
and intensive oral rehydration with 
fluids containing water, salt and sugar is 
encouraged.(59)
 
 Pharmacological intervention with 
standard dose loperamide (4 mg, 
followed by 2 mg/4h or after every loose 
stool) may be helpful with relieving 
diarrhea.(59) 
 For the management of nausea 
and vomiting, pharmacists should ask 
patients to eat small amount frequently 
and they should take plenty of fluids. 
Premedication with antiemetics like 
dimenhydrinate to limit drug-induced 
nausea and vomiting may be helpful.(59)
Hypertension
Hypertension is a common adverse 
event associated with VEGF 
inhibitors treatment. Risk assessment 
of hypertension and CV events should 
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be conducted before starting VEGFR 
TKI treatment. Active monitoring of blood 
pressure throughout treatment especially 
in first 6 weeks of treatment is required. 
Healthcare professionals should be 
aware of “white coat hypertension” 
and this factor should be carefully 
evaluated.(60) The goal for BP control of 
VEGFR TKI treated patients should be 
140/90 mmHg at maximum. However, 
the targets should be lowered with 
other preexisting comorbidities such as 
diabetes or chronic kidney disease.(60) BP 
control should be carried out aggressively 
so as to avoid the development of 
complications (such as CV events) 
associated with prolonged elevation. 
Normal antihypertensives (ARB, ACEI, 
diuretics etc.) may be useful in controlling 
BP(59) and its choice is up to prescribers. 
However, pharmacists should be aware 
of potential drug-drug interactions due to 
the CYP3A4 substrates nature of most 
targeted therapy for RCC.
Hematological toxicities
Serious hemorrhage and infections are 
possible severe adverse events caused 
by anticancer targeted therapy. CBC 
and physical examination should be 
conducted routinely to assess platelet, 
white blood cell and hemoglobin counts. 
Patients should be educated to avoid 
cuts, bruises and burns by avoiding 
physical activities with increased risk of 
bleeding.(59) Also, constipation should be 
treated and medications that may cause 
bleeding such as nonsteroidal anti-
inflammatory drugs (NSAIDs) should 
be avoided.(59) Also, systemic therapy 
especially bevacizumab which may 
cause wound healing problems should 
be discontinued before surgery and not 
restarted until adequate wound healing 
has occurred.(61)
Respiratory toxicities
Pneumonitis and interstitial lung diseases 
are complications associated with mTOR 
inhibitors treatment. Patient education 
is important to encourage reporting of 
symptoms such as cough and dyspnea. 
Once pneumonitis is diagnosed, 
differentiation between infectious and 
non-infectious pneumonitis is important 
as different treatment strategies would 
be used.(32) Corticosteroid and antibiotics 
could be used as treatment and dose 
interruption may be required in symptoms 
progression. 
Lab abnomalies
Hypothyroidism is a class adverse effect 
caused by sunitinib and pazopanib 
treatment. Thyroid function has to 
be monitored regularly and patients 
should be educated about signs of 
thyroid dysfunction for reporting to 
physicians. Levothyroxine may be given 
to symptomatic patients with elevated 
TSH and dose adjustment should be 
based on lab results.(59) 
 Hyperlipidemia and hyperglycemia 
are associated with mTOR inhibitors 
treatment.(47,48) Pharmacists and 
healthcare professionals should be aware 
of the current medical history of patients, 
patients with diabetes and hyperlipidemia 
should be monitored more closely and 
assess whether current diabetes and 
lipid medications are sufficient.(59) Lipid-
lowering medication and oral diabetes 
agents may be started or increased in 
dose to obtain control in cholesterol 
level and glucose level respectively. 
Also, pharmacists should advise patients 
to report excessive thirst or increase 
in volume or frequency of urination.(59) 
Moreover, hepatotoxicity may develop 
after long-term exposure of sunitinib 
and pazopanib,(51,53) thus bilirubin, ALT/
AST level should be routinely monitored. 
FUTURE TRENDS
Axitinib is an oral VEGFR TKI approved 
by the FDA in 2012 but has not yet been 
registered in Hong Kong. It is a VEGFR 
only inhibitor and indicated as second-
line treatment option for RCC after failure 
of prior systemic therapy. A randomized 
phase III study of 723 patients and 
axitinib showed significant benefit in PFS 
and ORR against sorafenib in treating 
refractory RCC patients and its safety 
profile is comparable to sorafenib.(49) 
 Tivozanib,(62) another oral VEGFR 
TKI undergoing a phase III clinical trial 
involving 517 patients, demonstrated 
significant improvement in PFS and 
ORR when compared with sorafenib 
without causing significant toxicity based 
on preliminary data.(63) Dovitinib, also 
another oral VEGF inhibitor demonstrated 
anti-tumor activity in a phase I study(64) 
targeting previously anti-VEGF treated 
patients. A phase III study is in progress 
to compare the efficacy with sorafenib in 
third-line RCC treatment.(65)  Novel agents 
targeting new biomarkers are under 
development, including vorinostat,(66) 
a histone deacetylase inhibitor, which 
is used in combination with anti-VEGF 
agents to exhibit antitumor effect, is 
under phase I/II study.
 Other than investigational drugs, 
clinical trials on combination therapy 
and adjuvant use of existing drugs are 
also under investigation. Head-to-head 
comparison(67) of sunitinib and pazopanib 
as first-line treatment for RCC patients 
is also undergoing to compare their 
efficacy and safety profile.
CONCLUSION
Recent molecular targeted therapies 
have increased the treatment options 
available for metastatic RCC patients to 
prolong their survival. Future research 
will focus on further understanding of 
biological pathways and identifying 
phenotype involved in drug response 
and resistance, thus novel agents could 
be developed to optimize treatment 
efficacy and safety. Moreover, current 
systemic treatment is limited to palliative 
care which aims to prolong progression 
free survival and improve quality of life 
but not curative. Uncovering adjuvant 
use of targeted therapy may further 
raise the role of systemic therapy in 
decreasing relapse rate of disease after 
nephrectomy, or even to attain complete 
remission.
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1.  Which reason may not explain 
the increasing trend in renal cell 
carcinoma (RCC) patients?
a Better imaging techniques 
b Increasing overall survival rate of 
RCC
c Rising number of people with 
risk factors
d Popularity in abdominal imaging 
scans
2.  Which risk factor contributes to 
potential development of renal 
cell carcinoma (RCC)?
a Alcohol abuse
b Long term opioid use
c Defect in Von Hippel-Lindau 
(VHL) gene
d Female
3. Which of the factor is least related 
in over-expression throughout 
the development of renal cell 
carcinoma (RCC)?
a Platelet derived growth factor 
(PDGF)
b Mammalian target of rapamycin 
(mTOR)
c Vascular endothelial growth 
factor (VEGF)
d Human epidermal growth factor 
receptor 2 (HER2)
4. Which of the following statement 
about Renal Cell Carincoma (RCC) 
staging is incorrect?
a If the tumor size is less than 
7cm with regional lymph node 
involvement, the estimated 
average 5 year survival rates in 
RCC is about 96%.
b Distant metastasis to any 
visceral organ indicates a stage 
IV carcinoma.
C If the tumor invades into vena 
cava with no lymph node 
involvement, the estimated 
average 5 year survival rates in 
RCC is about 64%.
d The Memorial Sloan-Kettering 
Cancer Center (MSKCC) 
model is adopted to determine 
prognosis of patients.
5. Which of the therapeutic option is 
considered reasonable in stage III 
renal cell carcinoma (RCC)?
a Radical Nephrectomy
b Thermal ablation therapy
c Targeted therapy
d Clinical trials
6. Which of the following statement 
about Renal Cell Carcinoma (RCC) 
therapeutic options is correct?
a Immunotherapy such as 
Interleukin-2 use is a viable 
treatment option in treating RCC 
based on its benefit in efficacy 
and safety.
b Temsirolimus should be used 
as first-line treatment option 
regardless of risk.
c Bevacizumab should be used 
in combination with IFN-α to 
maximize its efficacy in treating 
RCC.
d After approval of pazopanib, 
sunitinib was moved second-
line therapy due to its inferior 
efficacy.
7. Which of the following therapeutic 
agent involves in least drug-drug 
interaction?
a Sunitinib
b Temsirolimus
c Sorafenib
d Bevacizumab
8. Which of the adverse effect may 
be specifically related to sunitinib 
compared with sorafenib?
a Hand-Foot skin reaction (HFSR)
b Anemia
c Hypothyroidism
d GI perforation
9. Which of the adverse events 
management strategy may not 
regarded as appropriate?
a Intensive oral rehydration with 
electrolytes after an episode of 
diarrhoea is essential.
b Short-term application topical 
corticosteroids may be 
eff icacious for rel ieve 
dermatology symptoms such as 
rash.
c Medications that carry bleeding 
risk such as nonsteroidal anti-
inflammatory drugs (NSAIDs) 
and aspirin should be strictly 
forbidden.
D Levothyroxine may be a 
possible treatment option to 
sunitinib or pazopanib induced 
hypothyroidism.
10. Which of the following therapeutic 
agent is not a potential candidate 
for targeted therapy of Renal Cell 
Carcinoma (RCC)?
a Axitinib
b Tivozanib
c Ruxolitinib
d Dovitinib
2  CE Units
Overview of Targeted Therapies 
for Renal Cell Carcinoma
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Over-the-Counter Paracetamol for Management of Fever 
in Children
EWIG, Celeste L.Y. 
School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T.,  
Hong Kong SAR, China
ABSTRACT
Paracetamol has long been the 
drug of choice for relieving fever in 
children due to its easy accessibility, 
acceptable use in infants ≥3 months 
of age, and low side effect profile. 
However, as with any medication 
paracetamol is not exempt from 
errors due to incorrect doses and the 
potential for overuse. One possible 
reason for excessive use is fever 
phobia among parents. This phobia 
is largely due to misconceptions 
regarding the dangers of childhood 
fever and is reflected in studies which 
demonstrate parents’ tendency for 
lower temperature threshold in the 
definition of fever and associated 
harmful effects. Medication errors 
which have been documented 
include too frequent administration 
of paracetamol and administration of 
incorrect dose. Both present areas 
which pharmacists may contribute 
to improve medication safety among 
children. By counseling parents and 
caregivers regarding implications of 
fever, appropriate goals of therapy, 
and alert them on potential harmful 
effects associated with the use and 
misuse, we can ensure paracetamol 
maintains its status as the safe 
and effective drug of choice for the 
management of fever among children 
in the out-patient setting. 
Keywords: Over-the-Counter: Over-the-
Counter Paracetamol, Fever, Children 
INTRODUCTION
Over-the-counter antipyretic agents 
account for majority of medications used 
by children. Paracetamol in particular 
ranks as the single most commonly 
used over-the-counter medication in 
children in the outpatient setting. 
Although local data regarding the use 
of paracetamol among children in Hong 
Kong is currently unknown, overseas 
studies have documented the frequency 
of its use. In the United Kingdom, 
paracetamol accounted for 48.4% of 
total over-the-counter medications 
for children <16 years of age.(1) In the 
United States, paracetamol (known as 
Acetaminophen) represented 23% of the 
most used single-ingredient medications 
in infants ≤23 months of age, and the 
most used active ingredient among all 
children <12 years old.(2) Paracetamol’s 
popularity extends to children in Hong 
Kong as well due to its accessibility as 
an over-the-counter medication and its 
favorable safety profile. It is worthwhile 
to revisit the aspects regarding its use as 
an antipyretic among such population. 
This article explores paracetamol’s use/ 
misuse, associated harmful effects and 
ways by which pharmacists may improve 
the primary care provided to parents 
caring for children with fever in the 
community setting.
ANTIPYRETIC OF CHOICE OR 
CHOOSING TO OVER USE 
ANTIPYRETICS?
The presence of fever in a child has the 
tendency to illicit excessive concern 
among parents in Hong Kong- a 
phenomenon long recognized as fever 
phobia. A term coined by Schmitt, B. 
in 1980, fever phobia described his 
observations of parental behavior 
in children presenting with fever.(3) 
Despite its recognition 20 years ago, 
fever phobia remains a fully universal 
occurrence among parents with a 
febrile child.(4-6) Although difficult to 
establish an explicit causal relationship, 
fever phobia may be the underlying 
factor leading to aggressive treatment 
and over use of antipyretics such as 
paracetamol. 
 Fever is a symptom and not 
a disease itself. However, parents’ 
misperception of it as a disease is not 
uncommon. Reducing an elevated body 
temperature regardless of the degree 
of elevation becomes a primary focus 
rather than the overall condition of the 
child. The clinical definition of fever 
is a rectal temperature ≥38.0°C or an 
oral temperature ≥37.8°C.(7,8) Research 
regarding caregivers’ definition of fever 
have shown the tendency for parents to 
provide lower threshold temperature for 
the definition of fever with most assigning 
fever as any temperature above 37.5-
37.9°C.(9,10) 
 In addition to a lower threshold 
temperature for fever, parents’ were also 
found to regularly use medications to 
achieve normothermia when temperature 
readings are <38.5°C. This has been 
demonstrated by the persistence 
and increased frequency of use of 
antipyretics despite temperatures being 
only mildly elevated. Parent interviews 
have suggested this to be due to the 
perceived harm to the child as a result of 
elevated temperatures. The three most 
commonly cited harmful effects of fever 
(and thereby serve as the basis for fever 
phobia) include seizure, brain damage 
and death. A comparison of the findings 
from several studies looking into parents’ 
perceptions is listed in Table 1. 
 The lowest temperature threshold 
believed to pose a threat was 40°C with 
a good majority of parents believing that 
fever alone could damage a child.(10-13) 
Additional factors such as ethnicity 
appear to play a role as well in the 
overall fever management with parents 
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Harmful Effects of Crocetti et al Poirier et al Karwowska et al Betz et al
Fever (n= 340)  (n=230)  (n=209) (n=264)
Seizure 32% 32% 69.9% 19.4%
Brain Damage 21% 15% 53.1% 24.4%
Death 14% 18% 35.4% 5.3%
Dehydration 4%  80.4%
 American Academy  Medicines and Healthcare Therapeutic Goods 
 of Pediatrics(14) Products Regulatory  Administration
  Agency (UK)  (Australia)
Maximum Daily Dose  75mg/kg Dosing based on age 60mg/kg   
   (without medical advice)
Maximum Number of  ≤5 doses 4 doses 4 doses 
dose/ Day
Maximum days before  - 3 days 2 days 
seeking medical advise
Age cutoff for use <3 months <2 months <1 month
of East Asian origin more likely to seek 
clinician assistance immediately rather 
than attempting to first manage their 
child at home.(12,13) Against common 
misconception, fevers between 37.8°C to 
40°C are actually less often considered a 
threat. The risk for harm increases when 
temperatures reach at least 41.7°C. 
Adverse physiologic events begin to 
occur at temperatures above 41°C to 
42°C rather than the widely held belief 
of temperatures above 40°C. In practice 
though, few fevers escalate pass this 
point due to our brain’s natural capability 
to regulate temperature. 
TO GIVE OR NOT TO GIVE
Benefits of using antipyretics for fever 
reduction include relief of patient 
discomfort and minimizing insensible 
water loss to prevent dehydration. 
Additionally, paracetamol is also an 
analgesic. Benefits of its use include 
improved comfort in the child that then 
extends to improvements in activity, 
feeding, and reduced irritability. This 
allows the clinician to better assess the 
child’s condition. 
 It is important to note that the 
degree of fever does not always 
correlate with severity of illness or risk 
for febrile seizures, another common 
misconception. Additionally, antipyretic 
therapy may not necessarily decrease 
the recurrence of febrile seizures.(7) 
Deciding to initiate anti-pyretic therapy 
largely depends on several factors. Often 
clinicians may have a higher threshold of 
starting therapy when the child appears 
to be quite well, with eating and drinking 
patterns not too far from their usual 
norm. Unless the child is uncomfortable, 
antipyretics may not be necessary in 
patients with low grade fever. The age 
limit for use of paracetamol among 
infants is ≥3 months old unless under 
the care and instruction of a health 
care provider subsequent to clinical 
examination. The MHRA guidelines in 
the UK noted that paracetamol may 
be given to children as young as 2 to 3 
months old in the community setting only 
if the child experiences post-vaccination 
fever or if other causes of pain or fever 
exist and the infant weight >4 kg and was 
born after 37 weeks.(14) The drug also 
demonstrates a favorable safety profile 
compared to ibuprofen although their 
differences are quite marginal.(15)
 With all the benefits of fever 
reduction, the presence of fever does 
pose some advantages. Fever is a 
physiological adaptive response to 
external pyrogens such as micro-
organisms which causes the body to 
enhance elimination of certain bacteria 
and decrease bacterial and viral growth 
rates. Additionally, fever may assist the 
clinician in assessing the child’s condition 
and thereby preventing the delayed 
identification of the underlying diagnosis 
and initiation of treatment. 
MANAGEMENT OF CHILDHOOD 
FEVER IN THE OUTPATIENT SETTING
Recommendations for Paracetamol 
Dosing
Paracetamol at doses of 10 to 15 mg/
kg per dose given every 4 to 6 hours 
orally is generally regarded as a safe 
and effective dose range. Approximately 
80% of children will experience the 
onset of antipyretic effect within 
30 to 60 minutes.(7) The maximum 
recommended dose as well as maximum 
number of times paracetamol may be 
given in children vary.  A comparison of 
recommendations set forth by leading 
health organizations is shown in Table 
2. Although some authorities have 
accepted higher paracetamol doses, 
such as in the range of 90 mg/kg/
day, this dosing is regarded as supra-
therapeutic. Reminding parents that 
paracetamol will lower the fever but may 
not necessarily bring the child’s body 
temperature to normal may prevent over 
treatment. Parents may also be informed 
that if the child’s condition is stable, 
there is no need to awaken them during 
sleep to administer a dose. The benefit 
of allowing the child full interrupted rest 
outweighs dose administration.   
 Currently, there are no specific 
dosing recommendations for Hong 
Kong regarding use of over-the-counter 
paracetamol. Moreover, package 
labeling often indicate an age-based 
dosing guideline rather than the 
recommended weight based approach. 
Discrepancies in dose given may occur 
due to differences in weight among 
children’s even within a few years apart. 
To illustrate, a population based study 
done to determine the median age of 
Hong Kong boys at 3 years of age was 
found to be 14 kg while those 5 years of 
age was 17kg.(16)  If the same amount, 
for example 6 mL of paracetamol 120 
mg/5mL was given to children of both 
ages, a 3 year old boy will receive the 
recommended 10 mg/kg dose while a 5 
year old boy will receive a dose of 8 mg/
kg. This may cause a sub-therapeutic 
antipyretic effect leading to parents to 
give doses sooner than recommended 
or seek alternative measures. In 
products where weight based dosing 
indicates the approximate volume 
to administer, pharmacists should 
emphasize on the appropriate dose 
frequency to ensure the maximum daily 
limit is not reached. 
Table 1. Comparative findings of parents ‘perceived harmful effects of fever
Table 2.  Comparison of Paracetamol Recommendations
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 Alternating between paracetamol 
and ibuprofen or use of them in 
combination has been noted in practice 
to reduce body temperature. Experts 
agree that currently there is insufficient 
evidence to either accept or refute 
this practice. Clinicians who choose 
to recommend this approach should 
thoroughly counsel parents regarding 
proper formulation, appropriate dose and 
dosing frequency of each antipyretic.(7) 
Risks associated with use
When administered appropriately, 
paracetamol at doses of up to 75mg/
kg/day has not been associated with 
hepatotoxicity based on the results 
from a recent meta-analysis. However 
when used in an outpatient setting, 
dose accuracy is often compromised, as 
administration is dependent on accuracy 
of measurement by parents or caregivers. 
Inaccuracy of dose given by caregivers 
has been documented in numerous 
studies. In one study, 62% of patients 
who received acetaminophen were given 
an incorrect dose- 47% were given too 
little while 15% received too much.(17) 
This could be attributed to the parents’ 
lack of knowledge regarding appropriate 
dose to administer. A study by Li et al 
reported that although 55% of caretakers 
obtained dosing information from 
their physician, 28% of the caregivers 
followed package labeling with 8% of 
them resorting to guessing. 
 Incorrectly using standard measuring 
devices has also been documented. 
Proposed measures to reduce dosing 
errors include the use of color-
coded devices and pictograms.(9,18,19) 
These approaches have shown marked 
improvement from conventional methods 
in the caregivers’ ability to correctly 
determine and measure the appropriate 
dose for the child.(18,19) Interestingly, 
caregivers who correctly stated that 
paracetamol dosing is based on weight 
of the child were less likely to give an 
incorrect dose of medication.(18)
 Despite its good safety profile, 
paracetamol has also been linked to 
toxicity cases. Due to its popularity 
paracetamol has become a staple in 
most household’s medicine cabinet. This 
makes it readily accessible to young 
children. A review of hospital admissions 
in a local tertiary hospital during a 6 
year period observed paracetamol to 
account for 14 hospital admissions due 
to unintentional poisoning.(20) Fever has 
been documented to be predisposing 
factor for doctor shopping in the local 
paediatric population. The prevalence of 
this behavior was as high as 53% among 
paediatric in-patients.(21) Doctor shopping 
is associated with potential dangers 
such as polypharmacy from use of 
multiple medications often with multiple 
ingredients. Patients may inadvertently 
be taking several medications which 
contain paracetamol leading to toxicity. 
Pharmacists should be reminded to 
extend their counseling to include 
proper storage and avoidance of doctor 
shopping to prevent accidental over-
ingestion.
TAKE HOME MESSAGE
Paracetamol is a widely accessible 
drug often passed off as relatively safe 
due to its appropriateness of use in 
children <6months of age and negligible 
side effects. However research has 
documented areas where pharmacists 
may provide improved patient care. 
When counseling parents’ regarding 
fever, emphasis should be made on the 
primary goal of antipyretic use, which is 
improving the child’s comfort rather than 
achieving normothermia. Pharmacists 
may also remind parents that the height 
of a child’s fever does not necessarily 
reflect seriousness of the illness. Rather, 
it is how sick the child behaves that 
clinicians tend to weigh more heavily in 
their assessment. Fever is a symptom 
of a disease rather than a disease in 
itself and often times once the disease 
has been treated or addressed, the fever 
abates. If antipyretics are to be used, 
the recommended dose for infants and 
children is 10 to 15 mg/kg per dose every 
4 to 6 hours at a maximum of 4 doses per 
day. Fevers that persist beyond 48 hours 
despite use of paracetamol warrants 
medical attention. Educating parents on 
correct measurement and appropriate 
dosing frequency are additional areas 
where pharmacists can further enhance 
safety in the use of paracetamol for the 
management of childhood fever within 
the community setting.
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Figure 1. Percentage of population using traditional medicine, selected countries in the Western 
Pacific Region. [Adapted from Haq et al.(4)]
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Botanical name: Panax ginseng C. A. 
Mey.
Family: Araliaceae.
Common names/other names: Asiatic 
Ginseng, Chinese Ginseng, Korean 
Ginseng, Red Korean Ginseng, Ren 
Shen, Wonder-of-the-World, Bio Star, 
Cimexon, Energy Rise, Fast Lane Herbo 
Tea, Gincosan, Ginsana, Ginsatonic, 
Ginseng Action, Neo Ginsana
Chinese Name: 人參 rénshēn
Part Usually Used: roots, leaves, stems, 
fruits, flower heads
Common Uses: Increasing strength, 
vitality and immune function; lowering 
high blood pressure aphrodisiac; 
stimulating type II diabetes treatment; 
treating erectile dysfunction.
ABSTRACT
Panax ginseng C. A. Mey (P. 
ginseng), one of the most popular 
and best-selling herbs worldwide, 
has been used as a valuable folk 
medicine for thousands of years. 
It contains triterpenoid saponins, 
polysaccharides, volatile oils, 
polypeptides, polysacetylenes, amino 
acids and other bioactive compounds. 
The major bioactive components of 
this herb are triterpenoid saponins, 
including ginsenosides Rb1, Rb2, Rc, 
Rg, Re and Rf.  Of which ginsenoside Rf 
is the most characteristic component. 
Biological vice, the herb has CNS-
regulating, substance metabolism 
improving, age-delaying, immune 
system boosting, hematopoiesis 
promoting, anti-myocardial-ischemia, 
endocrine-enhancing and anti-tumor 
effects. In this review, an emphasis 
has been placed upon the biological 
activity and clinical applications 
associated with ginsenosides, 
particularly with respect to some new 
discoveries based on recent studies 
from chemoprofing studies and 
system biology.  
vietnamensis (Vietnamese ginseng)(2) 
(Table 1). Ginsenosides showing various 
pharmacological effects have been 
isolated from roots, leaves/stems, fruits, 
and/or flower heads of Panax species.(3) 
Of all Panax species, both P. ginseng 
C.A. Meyer and P. notoginseng (Burk) are 
native to China and Korea and have been 
used for centuries. The former is one of 
several types of true ginseng;another is 
American ginseng (Panax quinquefolius). 
Notoginseng, although looks very similar 
to Asian ginseng when it comes to their 
main bioactive compounds, is not a 
true ginseng. When the dried root and 
rhizome of P. ginseng is used as Chinese 
medicine, its Chinese name is renshen; 
when the dried leaf of P. ginseng is used, 
its Chinese name is renshenye. In most 
cases, when it comes to P. ginseng, it 
refers to its dried root. 
 Recommended uses for Asian 
ginseng are numerous, including the use 
of the herb to support overall health and 
boost the immune system. Traditional and 
folk uses of ginseng include improving 
INTRODUCTION
Herbal products are commonly used 
in developing and developed countries 
for medicinal purposes. According to 
a study conducted by WHO, it was 
found that more than 50% of the world 
population have used botanical based 
medicines for their primary health care 
(Fig. 1). Amongst all the herbs, Ginseng 
is one of the most popular and bestselling 
herbal products.
 Ginseng is referred to species 
within the genus Panax (Araliaceae 
family), comprising of approximately 14 
species of slow-growing perennial plants 
with fleshy roots.(1) The English word 
ginseng is derived from the Chinese 
term rénshēn in reference to the root’s 
characteristic human-like forked shape, 
The most widely used species of 
Panax are Panax. ginseng (Korean or 
Asian ginseng), Panax quinquefolium 
(American ginseng), Panax japonicus 
(Japanese ginseng), Panax notoginseng 
(Sanchi ginseng), and Panax 
Common name Botanical name
Asian ginseng (Chinese or Korean ginseng)a Panax ginseng C.A.Meyer
American ginsenga Panax quinquefolium L.
Japanese ginseng Panax laponicus C.A. Meyer
San-chi or Tien-chan ginsenga Panax notoginseng (Burk)
Siberian or Russian or Eleuthero ginseng Eleutherococcus senticosus
Vietnamese ginseng Panax vietnamensis
a Most commonly used
Herbal Medicines & Nutraceuticals
Table 1. Medicinally used ginseng species
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Figure 2. Morphological features of P. ginseng. (A) Whole plant photo and its fruits; (B) Fresh root 
and dried root of P. ginseng; (C) Decoction pieces of P. ginseng; (D) P. ginseng based dishes.
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Figure 3. Microscopic features of transverse section of Radix Ginseng (A). (1c) Sketch: (2c) 
Section illustration: (3c) Resin cannal: (4c) Cluster of calcium oxalate. 1. Cork: 2. Clefts: 3 Resin 
canna: 4. Phloem: 5. Cambium: 6. Xylem: 7. Clusters of calcium oxalate. Microscopic features 
of powder of Radix Ginseng (B). 1. Cork cells (surface view): 2. Cork cells (lateral view): 3. 
Resin cannal: 4. Resin canal with yellowish-brown secretion: 5. Single scalariform vessel: 6. 
Reticulated vessels in a group: 7. Single scalariform vessel with parenchymatous cells: 8. Single 
reticulated vessel: 9. Starch grains: 10. Cluster of calcium oxalate. a. Features under a light 
microscope, b. Features under a polarizing microscope. [Adopted from HKCMMS.(5)]
identified GL-3, GL-4, GL-5, GLA-3, 
GLA-4 and GLA-5, with molecular mass 
weight from 5000 to 8000, from the 
leaves of P. ginseng for the first time in 
1989.(7)  After 2 years, Gao et al. reported 
another four poly saccharides from the 
leaves of P. ginseng, including GL-NIa, 
GL-NIb, GL-AIa and GL-AIb.(8) A complex 
pectic polysaccharide (GL-4IIb2) from 
the leaves of P. ginseng, which was 
believed to be a macrophage Fc receptor 
expression-enhancing polysaccharide 
was reported by Shin et al.(9) Two acidic 
polysaccharides, named PA and PB, 
were isolated form the roots of P. ginseng 
by Tomoda et al.(10) Recently, Zhang et al. 
adopted a combination method of ethanol 
precipitation, ion-exchange and gel 
have attracted more and more attention 
by researchers due to their various 
biological activities used in food and 
medicine. Many biological active 
polysaccharides have been isolated 
from the leaves, roots or fruits of P. 
ginseng. Since the first research on P. 
ginseng polysaccharide reported, there 
were total 35 polysaccharides identified 
from the leaves, roots and fruits of P. 
ginseng up to date, including 16 ones 
came from the leaves, 18 ones from 
the roots and one from the fruits of P. 
ginseng. Kiyohara et al. investigated 
an anti-ulcer polysaccharide (GL-BIII, 
Rha, Ara, Man, Gal, Glc, GalA, GlcA 
in the ratio of 3:4:2:10:1:7:4) isolated 
from leaves of P. ginseng.(6) Gao et al 
the health of people recovering from 
illness; increasing a sense of well-being 
and stamina; improving both mental 
and physical performance; treating 
erectile dysfunction, hepatitis C, and 
symptoms related to menopause; and 
lowering blood glucose and controlling 
blood pressure. Despite those benefits 
mentioned above, adverse issues have 
benn reported. Further indepth and 
systematic studies of ginseng are still 
required to reveal their full potential uses 
as a medicinal herb.
DESCRIPTION AND IDENTIFICATION
Morphological and macroscopic 
features
Ginseng is a perennial umbel herb with 
weight of 10–15 g. The plant has white 
and fleshy roots and its primary root with 
several stout rootlets is about 7–10 cm in 
length and 3 cm in diameter. Numerous 
distinct “rings” (transverse wrinkles) are 
on the surface of the root because of the 
shrinking of the root, which is utilized for 
establishing the age of the plant. Ginseng 
is originally a self-pollination plant which 
starts to bloom at its third-year growth 
stage with flower buds removed for seeds 
and root growth. The stalk is straight and 
slender with cluttered red berries on the 
top of it where pale yellow seeds can 
be obtained. In general, its seeds are 
obtained from the red berries at its fourth 
year, each having 2 pale yellow seeds in 
it (Fig. 2).
Microscopic description
The transverse section illustrates cork 
comprising of several rows of cells; 
cortex is narrow. Phloem shows clefs 
in the outer part, and parenchymatous 
cells densely arranged and scattered 
with resin canals which contain yellow 
secretions in the inner part; cambium is 
in a rin and xylem rays are broad (2–26 
rows). Vessels are singly scattered 
or grouped in an interrupted radial 
arrangement, occasionally accompanied 
by non-lignified fibers; parenchyma cells 
containing abundant starch grains as 
well as clusters of calcium oxalate (Fig. 3). 
BIOACTIVE COMPOUNDS
Polysaccharides
A lot of researches have been conducted 
on the purification, structural analysis 
and bioactivities of polysaccharides 
from P. ginseng. Polysaccharides as 
biological response modifiers (BRMs) 
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Figure 4. Chemical structures of saponins in P. ginseng.
permeation chromatography to fraction 
water-soluble polysaccharides from 
the roots of P. ginseng into two groups, 
namely neutral (WGPN and WGPA-N) 
and acidic polysaccharides (WGPA-1-
RG, WGPA-2-RG, WGPA-1-HG, WGPA-
2-HG, WGPA-3-HG andWGPA-4-HG).(11) 
Ginsenosides 
Generally, ginsenosides (Fig. 4) are 
commonly considered to be the main 
active components in P. ginseng. 
Most ginseng ginsenosides belong to 
a family of steroids with a four trans-
ring rigid steroid skeleton. They are 
also referred to as ginsenosides, 
triterpenoid saponins or dammarane 
derivatives. More than 200 ginsenosides 
have been isolated from ginseng plants. 
Based on their aglycone moieties, 
ginsenosides can be divided into 20(S)-
protopanaxadiol (e.g., Rb1, Rb2, Rb3, 
Rc, Rd, Rg3) and 20 (S) protopanaxatriol 
(e.g. Re, Rg1, Rg2, Rh) types. 
Ginsenosides can also be classified into 
polar (e.g. Rg1, Re, Rb1, Rc, Rb, Rd) and 
less polar (e.g. Rg6, F4, Rk3, Rh4, Rg3, 
Rk1, Rg5 compounds. 
ISOLATIION AND ANALYSIS OF 
GINSENG
Sample preparation techniques
Extraction is the essential step for 
purification and recovery of various 
bioactive compounds from plant 
materials. Ginseng saponins have been 
extracted from ginseng based on the 
choice of solvents and use of heat and/
or mixing to increase the solubility of 
materials and the rate of mass transfer.(12) 
The conventional method includes heat-
reflux, Soxhlet, ultrasound-assisted 
extraction (UAE) and microwave-assisted 
extraction (MAE). Heat reflux extraction 
is a solid–liquid extraction, accomplished 
by allowing hot solvent to leach out the 
compounds from the solid tissue. This 
technique allows extraction of the solid 
at an elevated temperature without 
loss of solvent under evaporation. Kim 
et al. optimized the parameters of heat 
reflux method and applied it to extract 
panaxatriol (Rg group) and panaxadiols 
(Rb group) ginsenosides from fresh; air 
dried and powered adventitious roots 
of ginseng (P. ginseng).(13) Ultrasound-
assisted extraction improves both 
solvent penetration into plant materials 
and the release of intracellular product 
by disruption of the cell walls at lower 
temperatures, avoiding thermal damage 
to extracts and loss of volatile components 
in boiling. Wu et al. successfully extracted 
the ginseng saponins from ginseng 
roots and cultured ginseng cells.(14) 
Microwave-assisted extraction (MAE), as 
a relatively new extraction method, has 
been shown to enhance the extraction 
efficiency of interested components 
from a wide variety of sample matrices. 
It has been used as an alternative 
sample preparation technique for various 
applications.(15) Shu et al. used focused 
microwave-assisted technique to extract 
ginsenosides Rg1 and Rb1 from ginseng 
root under atmosphere pressure.(16)
Methods of analysis
Determination of ginseng saponins 
could be achieved by TLC or 
HPTLC; HPLC, HILIC or UPLC; gas 
chromatography (GC); multidimensional 
chromatography; or electrophoresis 
(CE). Among these techniques, liquid 
chromatography is used most frequently.
Thin-layer chromatography (TLC)
 
Versatility, speed, flexibility and low 
cost are the characteristic of TLC 
being used for tests of purity, quick 
qualification or species identification in 
pharmacopoeias and the pharmaceutical 
industry (Fig. 5). Vanhaelen-Fastré et al. 
optimized a densitometric determination 
of six major ginsenosides in P. ginseng, 
separated by high-performance thin-layer 
chromatography (HPTLC).(17) A fingerprint 
pattern with HPTLC discriminates white 
and red P. ginseng, P. quinquefolius 
and P. notoginseng. Xie et al. used high 
performance thin-layer chromatography 
(HPTLC) fingerprint analysis.for species 
authentication of a wide range of species 
of ginseng (P. ginseng, P. quinquefolium, 
P. notoginseng) and stability of 
ginseng preparations.(18) However, the 
application of thin-layer chromatography 
(TLC) or high-performance thin-layer 
chromatography (HPTLC) is limited by 
the poor sensitivity and specificity of 
the detection of ginsenosides whose 
electronic spectra shows no characteristic 
absorption above 215 nm.
Gas chromatography (GC) 
GC is a sensitive technique for detecting 
volatile chemical compounds or non-
volatile compounds readily derivatized. 
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Figure 5. TLC results of extracts from 
Panax Ginseng. The plates were placed in 
a 20×20 cm TLC tank containing about 110 
mL of the mobile phase prepared by mixing 
1,2-dichloroethane–100% ethanol–methanol–
water, 56.8:19.2:19.2:4.80 (v/v %) and 
developed at 4°C over a path of 10 cm for 30 
min. The ginsenosides were quantified by UV 
absorbance at 275 nm in the reflectance mode 
using a densitometer. [Adapted from http://
www.ginbiotic.com/en/product-information/
ginsenosides/ginsenosides-analysis]
Figure 6. HPLC chromatograms of ginseng 
extracts. (A) Asian white ginseng: (B) Asian 
red ginseng: (C) Chinese Shih-Chu ginseng: 
(D) Asian ginseng hairy roots. The peaks from 
(1) to (12) were Rb1, Rb2, Rc, Rd, Re, Rf, Rg1, 
Rg2, Ro, mRb1, mRb2 and mRc, respectively. 
[Adapted from Fuzzati.(28)]
(A)
(B)
(C)
(D)
The main constituents of ginseng are 
the non-volatile saponins, and much of 
the work in identifying and determining 
ginseng extracts has focused on the 
non-volatile fraction. Semi-volatile 
component of ginseng root, however, 
has proved to contain a number of 
sesquiterpenes, which may comprise 
a characteristic fingerprint containing 
sufficient chemical information to allow 
species differentiation.(19) Shellie et al. 
used comprehensive two-dimensional 
gas chromatography with flame 
ionisation detection (GC-GC) and with 
quadrupole mass spectrometry detection 
GC-GC-qMS to analyze the semi-volatile 
oils of three ginseng species; P. ginseng, 
P. notoginseng and P. quinquefolium.(20)
Liquid chromatography (LC)
High-performance liquid chromatography 
(HPLC) is the most used technique for 
the analysis of ginsenosides because it 
is low-cost, readily available, and easy 
to use.(21) Zhu et al. has developed 
and validated a HPLC method for 
the simultaneous determination of 
11 triterpene saponins with four-
type aglycones (protopanaxadiol, 
protopanaxatriol, ocotillol and oleanolic 
acid types) in Ginseng drugs.(22) Fuzzati 
et al created a high-performance liquid 
chromatographic method for electrospray 
mass spectrometric analysis of 
ginsenosides in P. ginseng roots
(Fig. 6).(23) Li et al. determined saponins in 
P. notoginseng using high-performance 
liquid chromatography with evaporative 
light-scattering detection.(24) It had been 
showed that PLE combined with rocket 
column HPLC analysis could provide a 
rapid method for analysis of compounds 
in traditional Chinese medicines.(25) 
Pressurized liquid extraction (PLE has 
been tested as a fast and high efficiency 
extraction method for Chinese herbs. On 
the other hand, the rocket column with 
large internal diameter, short column 
length and smaller silica particle size, 
has been successfully applied in rapid 
analysis.(26, 27) Thus, PLE and rocket 
column HPLC analysis may provide a 
rapid quality control method for CMs on 
conventional HPLC system. Qian et al. 
successfully simultaneously determined 
flavonoid, saponins and polyacetylenes 
in Folium Ginseng and Radix Ginseng 
by pressurized liquid extraction and 
high-performance liquid chromatography 
coupled with diode array detection and 
mass spectrometry.(25)
chromatography (MEEKC) are put into 
the use of separating neutral ginseng 
saponins.(29) Wang et al. utilized a field-
enhanced sample injection with reverse 
migrating micelles to separate and 
concentrate ten ginseng saponins in 
P. notoginseng on-line.(30) Sensitivity 
was one magnitude higher than with 
the method by Glockl et al.(31) making 
it possible to determine two minor 
ginsenosides, Rh1 and Rg2. Cao et al.(32) 
used on-line dual sweeping based on 
borate complexation and enhancement 
of the organic solvent field enhancement 
for the preconcentration of ginsenosides 
Rf, Rg1, and Re in MEKC with nonionic 
Brij-35 micelles.
Matrix assisted laser desorption 
ionization time-of-flight mass 
spectrometry (MALDI-TOF/MS)
MALDI is a soft ionization technique 
used in mass spectrometry, allowing the 
analysis of biomolecules (biopolymers 
such as DNA, proteins, peptides and 
sugars) and large organic molecules 
(such as polymers, dendrimers and 
other macromolecules), which tend to 
be fragile and fragment when ionized by 
more conventional ionization methods. 
Taira et al. used mass spectrometric 
imaging (MSI) to localize ginsenosides 
(Rb1, Rb2 or Rc, and Rf) in cross-sections 
of the P. ginseng root at a resolution of 
100 μm and confirmed that ginsenosides 
were located more in the cortex and the 
periderm than that in the medulla of a 
lateral root, besides, it revealed that 
localization of ginsenosides in a root 
tip (diameter, 2.7 mm) is higher than 
that in the center of the root (diameter, 
7.3 mm).(33) Nagappan et al. utilized 
MALDI-TOF/MS to reveal the protein 
profile in the roots of both Asian ginseng 
(P. ginseng) and Indian ginseng (W. 
somnifera), with the aim of clarifying 
similarly- and differentially-expressed 
proteins.(34) Lai et al. acquired MALDI-MS 
spectra and showed different patterns 
of ginsenosides and small chemical 
molecules between P. ginseng and P. 
quinquefolius (Fig. 7), thus allowing 
unambiguous differentiation between the 
two Panax species based on the specific 
ions, intensity ratios of characteristic ions 
or principal component analysis.(35) 
Two-dimensional gel electrophoresis
Two-dimensional gel electrophoresis, 
abbreviated as 2-DE or 2-D 
electrophoresis (Fig. 8), is a form of 
gel electrophoresis commonly used to 
analyze proteins. Mixtures of proteins 
could be separated by two properties 
in two dimensions on 2D gels. Ma et al. 
Micellar electrokinetic 
chromatography (MEKC) and 
microemulsion EKC (MEEKC)
Micellar electrokinetic chromatography 
(MEKC) and microemulsion electrokinetic 
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Figure 7. MALDI–TOF/MS spectrum in mass region of 1100–1400 for P. ginseng (A) and 
P. quinquefolius (B) respectively; (C) The intensity ratio of m/z 1147 to m/z 1117, which was 
regarded as a marker for authentication of P. ginseng, in the MALDI–TOF/MS spectra obtained 
for P. ginseng and P. quinquefolius; (D) PCA plot of the MALDI–TOF/MS results for P. ginseng, 
P. quinquefolius and mixed ginseng samples. [Adapted from Lai et al. (35)]
(A)
In
te
ns
ity
 (%
)
(C)
(B)
0
0 1 2-2 -1
1
2
0
2
4
6
8
10
12
14
-2
-1
P
C
2
Panax quinquefolius
Panax quinquefolius
U.S.A
I 1
14
7/
 I
11
17
Canada China
Panax ginseng
Panax ginseng
Mixture
PC1
(D)
Figure 8. Ginseng proteomic patterns with different ages, from one to five years old for (A) to 
(E), respectively. [Adapted from Ma et al.(36)]
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Figure 9. Synchronous 2D-FTIR correlation spectra of (A) P. ginseng: (B) P. quinquefoliu: (C) 
P. notoginseng in the region of 850–1180 cm–1 with their curves of auto-peaks in the 2D-FTIR 
spectra for: (D) P. ginseng: (E) P. quinquefolius: (F) P. notoginseng. [Adapted from Lu et al.(39)]
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for the first time employed proteomics 
and biochemical variables to unravel 
the growth strategies for the different 
root growth periods of P. Ginseng by 
2-DE, showed 83 differentially expressed 
spots, and explained the interaction of 
metabolic proteins associated with the 
growth strategies of ginseng.(36) Kim 
et al. Detected the most abundant root 
proteins of ginseng (P. ginseng) and 
identified them by comparative proteome 
analysis with cultured hairy root of 
ginseng.(37) Kim et al. also detected more 
than 300 protein spots on silver stained 
two-dimensional (2-D) gels using pH 
3–10, 4–7, and 4.5–5.5 gradients. Major 
protein spots were analyzed by peptide 
fingerprinting or de novo sequencing and 
the functions of 91 of these proteins were 
identified.(38) 
Fourier transform infrared 
spectroscopy 
The herbal materials of Asian ginseng 
(the root of P. ginseng), American 
ginseng (the root of P. quinquefolius) 
and Notoginseng (the root of P. 
notoginseng) had been difierentiated 
by conventional Fourier transform 
infrared spectroscopy (1D-FTIR), when 
two-dimensional (2D) correlation FTIR 
applying a thermal perturbation is used, 
it is a powerful analytical method, as 
shown in Fig. 9, each species could be 
well differentiated.(39) 
BIOLOGICAL EFFECTS
Preventing cancer and activate 
antitumor immunity
In vitro, ginsenosides stimulated the 
apoptosis of human hepatocarcinoma SK-
HEP-1 cells, rat glioma C6Bu-1 cells, SK-
N-BE human neuroblastoma cell, human 
melanoma A375-S2 cells and prostate 
carcinoma LNCaP cells. Finsenosides 
also induced the differentiation of Morris 
hepatocarcinoma, B16 melanoma 
and F9 teratocarcinoma, and inhibited 
the angiogenesis and metastasis of 
12-O-tetradecanoylphorbol-13-acetate 
and H2O2 in WB-F344 rats 
and reduced the carcinogenic 
acitivity of methycholanthrene.(40, 41) The 
polysaccharides and panaxynol inhibited 
the proliferation of promyelocytic 
leukemia HL-60 cells Results of 
epidemiological studies of P. ginseng 
intake and cancer cases (4600 patients) 
indicated that those who took P. ginseng 
were less likely to contract various 
cancers such as stomach, liver and lung 
cancers. Increased intake leads to a 
lesser ratio of danger, demonstrating its 
value for primary prevention.(42, 43) Suh 
et al.(44) monitored cancer recurrence in 
people diagnosed with stage III gastric 
cancer by giving 4.5 g/day of red ginseng 
for 6 months. People were followed up 
for 4.5 years after treatment, and there 
was a significant reduction in cancer 
recurrence (RR 0.49 [0.25, 0.98]). Yun 
et al. monitored incidence of cancer in 
people with chronic atrophic gastritis 
HKPJ   VOL 20  NO 1   Jan-Mar 2013
38
HKPJ   VOL 20  NO 1   Jan-Mar 2013
39
Figure 10. Ginseng can increases apoptosis and reduce proliferation in AOM/DSS-induced 
tumors from mice. (A) HE stained tumor from mouse on normal diet (20×); (B) HE stained 
tumor from mouse on normal diet supplemented with 250 ppm P. ginseng extract (20×); (C) 
Ki67 in tumor from normal diet fed mouse (20×); (D) Ki67 in tumor from mouse on normal diet 
plus ginseng (20×); (E) TUNEL staining in tumor from normal diet fed mouse (20×); (F) TUNEL 
staining in tumor from mouse on normal diet with P. ginseng (20×). Inset 40 × magnifications. 
[Adapted from Dougherty et al.(46)]
(A)
(D)
(B)
(E)
(C)
(F)
Figure 11. Possible cellular and molecular mechanisms of ginsenosides against cancer. 
[Adapted from Nag et al.(47)]
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who were given 1 g/week of red ginseng 
for 3 years. Participants were followed 
up for 8 years after treatment, and there 
was a notable reduction in incidences of 
cancer (RR 0.49 [0.21, 1.13]).(45) 
Histological monitoring revealed that 
ginseng can increase apoptosis and 
reduce proliferation of tumors from mice, 
as shown in Fig. 10.(46) The possible 
cellular and molecular mechanisms 
of ginsenosides against cancer were 
illustrated in Fig. 11.(47)
Increasing immunization functions
Ginsenosides promoted the cytophagic 
activity of blood colloid carbon particles, 
and increased the production of 
antibodies in several animals. The 
polysaccharides raised the serum anti-
IgH Level in mice treated with sheep 
red blood cells. Scaglione et al.(48) 
conducted two studies that followed the 
same protocol, using 200 mg G115 or 
PKC for 8 weeks. Immune cell activity 
and numbers were measured at the end 
of treatment. Significance for G115 and 
PKC was observed, chemotaxis (G115, 
MD 0.53 [0.19, 0.87]; and PKC, MD 
0.52 [0.19, 0.85]) and total lymphocytes 
(PKC, MD 5.82 [0.89, 10.75]). Jung 
et al.(49) investigated post-exercise 
muscle damage and inflammation after 
administration of 60 g of red ginseng to 
healthy people for 10 days. In that time, 
creatine kinase significantly deceased 
(MD 39.50 [65.98, 13.02]), indicating 
reduced muscle damage. Insulin 
sensitivity also improved (MD 1.40 [0.52, 
2.28]) possibly because of reduced 
muscle damage.(50)
 A water-soluble ginseng marc 
polysaccharide (GMP) was examined 
for immunomodulatory effects in murine 
peritoneal macrophages by Lim et al.(51) 
Results suggested that GMP was an 
effective nonspecific immunomodulatory 
agent, and its immuno-stimulating effects 
may be due to its ability to stimulate 
the production of reactive oxygen 
intermediates.
Improving blood circulation
The root produced a biphasic effect on 
the heart, excitatory at low doses and 
inhibitory at high doses. Ginsenosides 
reduced the heart rate of dogs and 
rats, prolonged contraction time in 
guinea pig isolated atria under hypoxia, 
decreased the lactic level in ischemic 
coronary sinus, increased tolerance 
to hypoxia, prevented arrhythmias 
caused by barium chloride, and 
reversed tachycardia. Reports have 
showed ginseng’s inhibitory effects on 
platelet aggregation(52) and endotoxin-
induced disseminated intravascular 
coagulation.(53) The role of ginsenoside 
Rg3 in the inhibition of platelet 
aggregation has been described.(54) The 
role of ginsenosides in protecting human 
erythrocytes against hemin-induced 
hemolysis has been described.(55)
Antioxidant function
Kim and Lee studied the results of 
healthy smokers taking 1.8 g of red 
ginseng or placebo for 4 weeks, but 
no significant effect was reported.(56) 
Kim et al.(57) investigated the effect of 
P. ginseng at 1 or 2 g/day on healthy 
people for 4 weeks. Lipid peroxidation 
decreased with low and high doses, 
MD 1.50 [2.97, 0.03] and MD 1.80 
[3.20, 0.40], respectively. These studies 
showed evidence of P. ginseng’s 
antioxidant effect; however, other 
measured components, including total 
reactive oxygen species and antioxidant 
capacity, were not significant. Voces 
et al.(58) investigated the effect of 
prolonged treatment with the 
standardized P. ginseng extract G115 
on the antioxidant capacity of the liver. 
The results demonstrated that the 
administration of G115 significantly 
improves the hepatic glutathione 
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peroxidase activity (GPX) and the 
reduced glutathione (GSH) levels in the 
liver, with a dose-dependent reduction 
of the thiobarbituric acid reactant 
substances (TBARS).
The memory enhancing effects
The roots of P. ginseng contain 
several triterpene glycosides named 
ginsenosides (or panaxosides), which 
are believed to serve to the adaptogenic 
and physical performance enhancing 
properties of the ginseng extracts.(59) 
Published trials indicated beneficial 
effects of ginseng include those of 
D’Angelo et al.(60) demonstrating 
improvements on motor performance, 
and Rosenfeld et al.(61) and showing 
benefits on neuro-psychological 
measures. Beneficial effects on memory 
have also been reported in animals(62) 
there have also been indications 
of benefits for cognitive functioning 
from ginseng in both humans(63) and 
animals. Wesnes et al.(64) conducted 
an experiment on healthy middle-aged 
volunteers to test the memory enhancing 
effects of a Ginkgo biloba/P. ginseng 
combination, and the results showed the 
Ginkgo/ginseng combination significantly 
improves an Index of Memory Quality.
Anti-radiation activity
Kim et al.(65) previously reported 
that an acidic polysaccharide from 
P. ginseng, namely ginsan. Ginsan 
was found to significantly increase 
the number of bone marrow cells, 
spleen cells, granulocyte-macrophage 
colony-forming cells (GM-CFC), 
circulating neutrophils, lymphocytes and 
platelets in irradiatedmice. Moreover, 
ginsan induced the endogenous 
production of cytokines such as IL-1, IL-
6, IL-12 and TNF-α, which are required 
for hematopoietic recovery.(66) Kim et al. 
also identified ginsan alter the phenotype 
of bone marrow cells, and increased 
the viability and alloreactivity of bone 
marrow cells after gamma radiation 
both in vitro and in vivo.(67) In addition, 
ginsan modulates the radiation-induced 
disturbance of antioxidant enzymes 
such as superoxide dismutase (SOD), 
catalase and glutathione peroxidase 
(GPx).(68) Recently, Park et al.(69) draw a 
conclusion that ginsan protected mice 
from radiation-induced damage of the 
small intestine via the lengthening of villi 
and a numerical increase of crypt cells 
in the small intestine at 3.5 days after 
7Gy irradiation compared to irradiated, 
non-treated controls. Additionally ginsan 
significantly decreased the amount of 
proapoptotic p53 and Bax to inhibit 
irradiation-induced apoptosis; on the 
other hand, it increased that of anti-
apoptotic Bcl-2 at 24 h after irradiation. 
Therefore, these results indicated that 
ginsan might be a useful candidate radio 
protective adjunct for cancer patients.
Hepatoprotective activity
The effects of polysaccharide ginsan 
from P. ginseng on liver function were 
analyzed by song et al.(70) The data 
illustrated that ginsan treatment did 
not seem to cause hepatic injury, 
since serum aspartate aminotransferase 
(AST), alanine aminotransferase (ALT) 
and alkaline phosphatase (ALP) activities 
as well as levels of total bilirubin and 
albumin were not changed. In order to 
make a good recognition for ginsan as a 
hepatopro tective formulations as well as 
combined application with other drugs, 
ginsan on carbon tetrachloride (CCl4)-
induced liver injury was examined in 
their next research.(71) BALB/cmice 
were injected intraperitoneal (i.p.) with 
ginsan 24 h prior to CCl4 administration. 
Serumliver enzyme levels, histology, 
expression of antioxidant enzymes, 
and several cytokines/chemokines 
were sub-sequently estimated. The 
results suggested that ginsan effectively 
prevented liver injury, mainly through 
down regulation of oxidative stress and 
inflammatory response.
CLINICAL APPLCATIONS
Enhanceing cognitive performance in 
Alzheimer disease
Protective and trophic effects of ginseng 
in the memory function of Alzheimer 
disease (AD) have been showed in 
several experimental evidences. Lee et 
al. investigated the clinical efficacy of 
P. ginseng in the cognitive performance 
of AD patients in an open-label study. 
Consecutive AD patients were assigned 
to the ginseng (n=58) or the control 
group (n=39) at random, with the ginseng 
group ingesting P. ginseng powder (4.5 
g/d) for 12 weeks. Mini-mental state 
examination (MMSE) and Alzheimer 
disease assessment scale (ADAS) 
were empolyed to monitor cognitive 
performances during 12 weeks of the 
ginseng treatment and 12 weeks after 
the ginseng discontinuation respectively. 
MMSE and ADAS scales showed no 
baseline difference between the groups. 
After ginseng treatment, the cognitive 
subscale of ADAS and the MMSE score 
began to show improvements and 
continued up to 12 weeks (P=0.029 
and P=0.009 vs. baseline, respectively). 
After cease of ginseng, the improved 
ADAS and MMSE scores decreased to 
the levels of the control group. These 
results demonstrated that P. ginseng is 
clinically effective in the cognitive 
performance of AD patients (Clinical 
Trials.gov Identifier: NCT00391833).(72)
Improving myocardial protection
Myocardial disease is the leading 
cause of mortality in industrialized 
nations. Ginseng has been utilized to 
treat heart failure and protect tissues 
from damage when an organism is 
under stress.(73) In 2010, Vuksan et al. 
developed and initiated the P. Ginseng 
Clinical Testing Program for vascular 
function which is an efficacy and safety-
based clinical screening model for 
ginseng. The most efficacious sources, 
ginsenoside profiles, doses, and modes 
of administration were examined in 
sequential, acute, followed by long 
term, randomized-controlled trials to 
investigate the efficacy and safety 
profiles.(74) Total ginsenosides inhibit 
right ventricular hypertrophy in rats(75) 
and nitric oxide functions in ginsenoside 
Rg1-induced protection against left 
ventricular hypertrophy in rats.(76) 
Wang et al. reported that Ginsenoside 
Rb1 preconditioning protects against 
myocardial infarction after regional 
ischemia and reperfusion by activation 
of phosphatidylinositol-3-kinase signal 
transduction.(77) Ginsenoside Re activates 
cardiac potassium channels via a 
nongenomic pathway of sex hormones(78) 
and ginsenoside Rb1 preconditioning 
protects against myocardial infarction 
after regional ischemia and 
reperfusion.(79) Wang et al. and Yook et 
al. suggested that P. ginseng suppresses 
apoptosis by regulation of Bcl-2 and 
caspase-3 during hypoxia/reoxygenation 
in neonatal rat cardiomyocytes.(80, 81) 
Besides, ginsenoside Rg1 protects 
rat cardiomyocyte from hypoxia/
reoxygenation oxidative injury via 
antioxidant and intracellular calcium 
homeostasis(82) and enhances 
angiogenesis and ameliorates ventricular 
remodeling in a rat model of myocardial 
infarction.(83) Moreover, compound K, 
a metabolite of ginsenosides, bestows 
nitric oxide-mediated cardiac protection 
via the Akt/phosphoinositol-3-kinase 
(PI3K) pathway.(84) Ginseng also protects 
from cardiac injury by acute myocardial 
ischemia-reperfusion in rodents through 
Gr/Er-activated risk pathway in an 
endothelial nitric oxide synthase (eNOS)-
dependent mechanism.(85) Guo et al. 
reported ginseng Iinhibits cardiomyocyte 
hypertrophy and heart failure via NHE-1 
inhibition and attenuation of calcineurin 
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Figure 12. Phenylephrine (10 μmol/L) treatment on calcineurin activity, NFAT3 translocation, 
and the DNA-binding activity of GATA-4 with/without of 10 μg/mL ginsenosides. (A) Calcineurin 
activity of PE treated cells with/without ginsenosides for 0.15 to 24 hours: (B) Immunofluorescent 
images of NFAT3 translocation into nucleus in PE treated cells with/without ginsenosides for 24 
hours: (C) Western blots and quantification of GATA-4 phosphorylation. D, GATA-4/DNA-binding 
activity in the PE treated cells with/without ginsenosides. Data are shown as means±SEM. 
*P<0.05 versus control; #P<0.05 versus PE, n=3 to 5. Ctl, control; Gins, ginsenosides; PE, 
phenylephrine. [Adapted from Guo et al.(86)]
activation(2) (Fig 12). The collective 
data conclusively showed that ginseng 
protects the heart from myocardial 
damage.
Adjusting blood lipid profile
It is well known that high blood 
cholesterol level is one of the three major 
risk factors of coronary heart disease, 
which is one of the leading causes of 
death in the world. Given the fact that 
people who have metabolic syndrome 
are susceptible to atherosclerotic 
myocardial diseases,(87) effective and 
feasible therapeutic strategies are 
urgently needed for the treatment of 
complications of metabolic syndrome. 
In recent years, more attention has 
been paid to bioactive components from 
P. ginseng. Particularly, it was reported 
that P. ginseng saponin reduces weight 
gain in mice.(88) Kim et al. examined 
the effects of P. ginseng extract 
on lipid metabolism in humans by 
measuring cholesterol, malondialdehyde, 
superoxide dismutase, and catalase 
and found that the hypolipidemic effect 
of P. ginseng extract is associated with 
a decrease in serum total cholesterol, 
triglyceride, low density lipoprotein, 
malondialdehyde levels and an increase 
in high density lipoprotein, which support 
scientific claims that ginseng has the 
hypolipidemic potential.(89) P. notoginseng 
saponins attenuate atherosclerosis by 
regulating the lipid profile and have 
an antiinflammatory action in rats,(90) 
and atherosclerosis is inhibited by 
total ginsenosides in apolipoprotein 
E-knockout mice.(91) P. notoginseng 
attenuates hypercholesterolemia 
enhanced platelet aggregation by 
suppressing diacylglycerol liberation in 
rabbits fed a diet high in cholesterol.(92) 
Jia et al. reported that ginseng saponins 
could significantly decrease the level of 
cholesterol ester in foam cells at middle 
and high dosages, the expression of 
ABCA1 was up-regulated by PNS in 
a dose-dependent manner, and the 
cholesterol ester level was negatively 
correlated with ABCA1 expression.(93) 
The antihyperlipidemic effects of acidic 
polysaccharide from P. notoginseng were 
reported.(94) P. notoginseng saponins 
attenuate atherogenesis in rabbits,(95) 
and radix notoginseng has hypolipidemic 
and antioxidant activities in rats fed a 
high fat diet.(96) Ginsenoside-Rd prevents 
atherosclerosis in ApoE-knockout mice.(97)
Adjusting blood circulation
Reports have showed ginseng’s, 
especially Rg3, inhibitory effects on 
platelet aggregation(98, 99) and endotoxin-
induced disseminated intravascular 
coagulation.(100) The P. ginseng 
significantly prevented rat carotid arterial 
thrombosis in vivo in a dose-dependent 
manner and inhibited adenosine 
diphosphate (ADP)- and collagen-
induced platelet aggregation ex vivo.(101) 
The role of ginsenosides in protecting 
human erythrocytes against hemin-
induced hemolysis has been noticed.(102) 
Screening of antiplatelet aggregation 
agents from P. notoginseng can be done 
using human platelet extraction.(103) P. 
notoginseng saponins improve the post-
treatment effects on lipopolysaccharide 
induced microcirculatory disturbance in 
rat mesentery.(104) Anti-platelet and anti-
coagulant effects of P. notoginseng were 
described in a comparison of raw and 
steamed P. notoginseng with P. ginseng 
and P. quinquefolium(105) Ginsenoside 
Rk1 and Rg5 inhibited arachidonic 
acid and U46619 induced platelet 
aggregation in a dose dependent 
manner, while ginsenoside 20(S)-Rg3 
and 20(R)-Rg3 showed mild inhibitory 
activity against arachidonic acid and 
U46619-induced aggregation.(106, 107) 
Another study documented the 
interaction between warfarin and Asian 
red ginseng in patients with cardiac valve 
replacement.(108) Total ginsenosides 
dose-dependently and significantly 
increased coronary perfusion flow and 
improved systolic and diastolic function 
of the ischemia/reperfused rat heart, 
while inhibitors of NO synthase, soluble 
guanylate cyclase, heme oxygenase, 
cyclooxygenase, and potassium channel 
abolished the vasodilation effect of total 
ginsenosides.(109) Red ginseng extract 
improves coronary flow reserve and 
increases absolute numbers of various 
circulating angiogenic cells in patients 
with acute myocardial infarction.(110) 
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Figure 13. Estrogen binding equivalents of 
extracts of P. ginseng and P. quinquefolius 
from ERα and ERβ competitive binding assays 
and zearalenone concentrations determined 
by HPLC. [Adapted from Gray et al.(131)]
Overall, these results indicate that 
ginseng may improve blood circulation 
by inhibiting platelet aggregation and 
coagulation activity.
Adjusting blood pressure
Ginseng use was once misunderstood 
to increase blood pressure to unhealthy 
levels. Actually, it can elevate blood 
pressure, and this generally occurs with 
low blood pressure, which helps restore 
blood pressure to normal level; ginseng 
also lowers high blood pressure.(111) 
Biochemical and pharmacological 
activities of ginseng related to blood 
pressure control are being clarified with 
continued research. The vasodilation 
action of P. ginseng improves blood 
circulation.(112) Panxa ginseng has 
an antihypertensive effect, which 
appears to be related to lower rather 
than higher doses of ginsenosides.(113) 
Furthermore, the capacity of lowering 
the blood pressure of P. ginseng is due 
to promotion of vascular endothelial cell-
derived nitric oxide (NO) secretion.(114) 
In addition, a mixed aqueous extract of 
salvia miltiorrhiza and P. notoginseng 
demonstrated anti-hypertensive effects 
by inhibition of arterial myogenic 
responses.(115) The collective 
observations indicate that ginseng 
normalizes blood pressure and improves 
blood circulation.
Regulating intracellular ion channels
Jeon et al. investigated the effect of 
crude saponin and non-saponin fraction 
of Asian red ginseng on the blood 
pressure and nitric oxide production 
in the conscious rats and cultured 
endothelial cell line, ECV 304 cells, 
and the results showed the hypotensive 
effect induced by crude saponin reached 
maximum at 2–4 min and slowly 
recovered after 20 min to the initial 
level.(116) Rb1 treatment can inhibit the 
right ventricular hypertrophy induced by 
monocrotaline, which may be involved in 
its inhibitory effects on calcineurin signal 
transduction pathway.(117) Ginsenoside 
Rd reverses basilar hypertrophic 
remodeling in stroke-prone renovascular 
hypertensive rats as a new voltage-
independent Ca2+ entry blocker.(118) 
The cardiac therapeutic effects of 
ginseng and sanqi was reported to be 
partly attributed to the effective inhibition 
of Na+/K+-ATPase by their metabolized 
ginsenosides with sugar moieties 
attached only to the C-3 position of the 
steroid-like structure.(119) Another study 
reported that Rg3 inhibition of L-type 
Ca2+ channel currents is attenuated 
by mutations of Leu427, Asn428 and 
Leu431 in transmembrane domain-I-
segment 6 residues.(120) The data indicate 
that ginsenosides inhibit Ca2+ entry, and 
so may ameliorate cardiac function.
Regulating vascular endothelial cells
Ginsenoside Rb1 has protective 
effects on human oxidized low-density 
lipoprotein injuring cells in vitro and can 
and can reverse the effects of oxidized 
low-density lipoprotein on nitric oxide, 
tissue-type plasminogen activator, and 
plasminogen activator inhibitor-1.(121) 
Water extract of P. ginseng exhibits 
angiogenesis by activating the PI3K/Akt-
dependent extracellular signalregulated 
kinase 1/2 and eNOS pathways in 
human umbilical vein endothelial 
cells.(122) Ginsenosides also exhibit 
angiomodulatory and neurological 
effects.(123) Besides, ginsensoside Re 
releases nitric oxide via membrane 
sex steroid receptors, resulting in Kca 
channel activation in vascular smooth 
muscle cells, promoting vasodilation and 
preventing severe arterial contraction.(124) 
Ginsenoside Rb1 may attenuate 
capillary morphogenesis by the action 
of oestrogen receptor beta agonist and 
induces the signaling pathway of NO 
production in human aortic endothelial 
cells.(125) Moreover, experiments using 
fluorescent transgenic mice established 
the angiogenic effect of ginsenoside 
Rg1 from P. ginseng.(126, 127) Compound 
K inhibits basic fibroblast growth factor-
induced angiogenesis through regulation 
of p38 mitogen-activat-ed protein 
kinase and Akt in human umbilical vein 
endo-thelial cells.(128) Ginsenoside Rg1 
induces angiogenesis via non-genomic 
crosstalk of glucocorticoid receptor and 
fibroblast growth factor receptor-1(129) 
and mediates the microenvironment-
dependent endothelial differentiation of 
human mesenchymal stem cells in vitro. 
Furthermore, ginsenoside Rb1 protects 
endothelial cell from damage and 
stimulates ghrelin expression caused by 
hyperhomocysteine.(130) These collective 
observations indicate that ginseng 
saponin protects vascular endothelial 
cells via cellular signaling pathway.
ADVERSE ISSUES
Mastalgia, Vaginal Bleeding and 
Gynaecomastia
Cell proliferations, induction of estrogen-
responsive genes, and isolated 
cases of adverse reactions such as 
postmenopausal vaginal bleeding and 
gynecomastia have been reported 
after ginseng treatment. Gray et al. 
developed estrogen receptor (ER) α 
and ERβ competitive binding assays 
using recombinant receptors and [3H]-
17β-estradiol to detect phytoestrogens 
in extracts of Asian ginseng root and 
the results indicated that root extracts 
contained substances that bound both 
receptor isoforms (Fig. 13).(131) A woman 
developed swollen, tender breasts with 
diffuse nodularity after taking ginseng 
powder regularly for 3 weeks, suggest 
that the preparation may have mild 
hormonal activity, since small quantities 
of oestrone, oestradiol and oestriol are 
present in ginseng root.(132) Five women 
aged between 25 to 40 years who 
had been taking ginseng for varying 
periods developed breast symptoms, 
particularly enlargement of the nipples, 
they also reported an increase in “sexual 
responsiveness”.(133) Ginseng has been 
reported to raise blood pressure, which 
may increase bleeding risk. A 72-year-
old postmenopausal woman developed 
vaginal bleeding after administration of 
200 mg of ginseng for one month,(134) and 
a 44-year-old postmenopausal woman 
reported vaginal bleeding after using 
a ginseng face cream.(135) Therefore, 
ginseng is best stopped before surgery. 
Diuretic resistance
It is reported that a 63-year-old man 
experienced diuretic resistance 10 
days after daily administration of 10 to 
12 tablets of a germanium-containing 
ginseng preparation (Uncle Hsu’s 
Korean ginseng). It is concluded that the 
problem was more likely to be caused by 
the germanium than the ginseng.(136)
Stevens-Johnson Syndrome
A 27-year-old man experienced typical 
Stevens-Johnson syndrome (bilateral 
conjunctivitis, dry cough, a macular 
rash on his face, painful erosions on 
his mouth and urogenital mucosa, 
corneal ulceration and widespread 
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purpuric macules) 3 days after taking 
two ginseng tablets a day for 3 days.(137) 
The patient stopped aspirin, local 
antibiotics (amylmetacresol, tyrochricin), 
and vitamin C 6 days before the onset 
of Stevens-Johnson syndrome. These 
drugs have short plasma half-lives or are 
not absorbed by the intestine; therefore, 
the authors postulated that ginseng could 
be responsible for the illness. 
Cerebral arteritis
Ryu et al, reported that a 28-year-old 
woman who experienced a severe and 
explosive headache after ingesting a large 
quantity of ethanol-extracted ginseng. 
Cerebral angiograms demonstrated 
“beading” appearance in the anterior and 
posterior cerebral and superior cerebellar 
arteries, consistent with cerebral arteritis. 
It was concluded that the close temporal 
association between administration of 
ginseng and cerebral arteritis indicated a 
causal relationship.(138)
Psychiatric conditions
A 35-year-old woman with depressive 
illness who was maintained on lithium 
carbonate and amitriptyline experienced 
a manic episode requiring hospital 
admission 10 days after interrupting 
her therapy and starting treatment 
with one tablet of ginseng a day. Her 
symptoms improved following cessation 
of ginseng and a return to her previous 
medication.(139) It is debatable whether 
the symptoms were not, at least in part, 
caused by the cessation of lithium. 
Five in-patients with diagnoses of 
schizophrenia were observed to become 
generally irritable, uncooperative with 
their treatment programs and overactive 
with disturbed sleep after smoking 
ginseng-containing cigarettes. After 
stopping smoking these cigarettes their 
behavior was seen to improve.(140)
Agranulocytosis
Four non-Chinese patients developed 
life threatening agranulocytosis while 
taking Chinese herbal medicines for 
relief of arthritis and backpain (Long Life 
Brand Ginseng Hui Sheng Tsaitsaowan 
and Sanlungpai Ginseng Hui Sheng 
Tsaitsaowan; Nan Lien Pharmaceutical 
Company Ltd. Hong Kong and Taiwan). 
Subsequent analysis of the herbal 
preparations revealed the presence 
of undeclared aminopyrine and 
phenylbutazone, both of which are known 
to cause agranulocytosis. The authors 
conclude that these contaminants were 
responsible for the observed symptoms 
in these patients.(141)
Eye symptoms
Two cases of ginseng adverse effect 
has been documented that mydriasis 
and disturbance were noticed on 
both eyes in accommodation. The 
systemic symptoms included dizziness 
and semiconsciousness, which may 
be related to hyperexitability of the 
sympathetic nerves (adrenergic nerves) 
due to ginseng abuse.(142) 
Hypertension
A young man presented to his doctor 
with hypertension, shortness of breath, 
dizziness and inability to concentrate. He 
had been taking ginseng supplements 
for three years. Following cessation of 
the ginseng supplements his symptoms 
improved and did not recur.(143) A female 
patient with hypertension, who was 
receiving no other medication, reported 
an increase in her blood pressure 
from between 160/90 and 240/100 to 
280/120 mm Hg following treatment with 
ginseng (Ginzin tablets, Ferrosan) for 
a few days.(144) Three to four days after 
cessation of the ginseng product her 
blood pressure had fallen to 240/100 mm 
Hg and treatment with a β-blocker was 
commenced.
Herb-drug Interactions
A 64 year-old woman with depression 
who ingested P. gingseng was reported 
to experience tremor, insomnia, and 
headache, which was cheated as the 
results of interactions with pheneizine. 
It was conclude that the gingseng 
increased cAMP levels, which was 
mostly responsible for this her-drug 
interaction.(145) Another case was 
documented that a 64-year-old woman 
with depression developed manic 
symptoms, hallucinations after taking 
P. gingseng tea and the cause was 
considered to be same with the previous 
one, interaction with pheneizine.(146) 
CONCLUSION
P. ginseng is a world-wide popular 
herbal medicine used for a broad range 
of indications. Quite a lot of clinical 
trials and systematic reviews are now 
available. The obtained conclusions 
vary but are still encouraging. Future 
deep clinical research in this area 
should be concerned with overcoming 
the methodological limitations of the 
previous researches. 
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A letter to the HK Pharmacy Conference Organizing 
Committee
Dear Organizing Committee, sub-
committee members, performers, 
singers, musicians, drama crews and 
helpers,
 Every year after the Conference, 
I often wrote to you saying that it was 
one of the best Conferences that we had. 
This year, I have no doubt in saying that 
it is the best Conference I have ever 
had – and trust me, I have seen them 
all. It is not because I am the Chairman, 
but because it has been so obviously 
successful right from the opening until 
the ending speech, and then everything 
in between. Its success was evidenced 
not only by the record participant number 
of 577, a 34% increase over the last 
year, but also by the big crowd of people 
staying right until the end of the second 
day’s plenary session. If it were possible, 
I would really like to shake everyone’s 
hand and say thank you.
Comfort Zone
About a year ago, I was still struggling 
whether to take up the Chair of the 
Conference for 2013. Some of you might 
not know, I have been declining the job 
every few years for the past 24 years. 
Although I used the excuse of being too 
busy, I was actually afraid to accept the 
daunting responsibility. I feared that I 
might ruin the Conference. I would rather 
stay on back stage to do internal co-
ordination, or even stand on the podium 
as a speaker presenting a topic I felt 
comfortable with. You see, I was reluctant 
to leave my comfort zone, just like most 
of us in daily life and routine work.
 But in the end, I said “yes” to the 
invitation. I was so “brave” because first 
of all I was going to retire, and indeed 
I expected myself to be less busy than 
before. Secondly, I was a little scared 
that once I left the pharmacy circle, 
people would forget all about me. But 
the real driving force was seeing that we 
now have a large number of young and 
enthusiastic pharmacists, and students, 
led by several mature, but still young, 
pharmacists doing all the work from 
planning to execution. I asked myself, 
“what else should I be worrying about?”. 
So I took advantage of your strength and 
grab the title of Chairman of the Silver 
Jubilee Conference. I would be kicking 
myself today had I not accepted the offer 
12 months ago. It is your success that I 
am capitalizing on. Thank you a whole 
lot.
Ms Chiang told me a story:
“Come to the edge,” we say.
“No, we are afraid,”
“Come to the edge,”
They come. We push. And they fly.
 I just realize today that I was the 
young birds after all these years. The 
lesson to learn is when you leave your 
comfort zone, you could really fly, no 
matter how young or old you are.
The program
The program is the heart of a professional 
conference, for it is the main purpose for 
having a conference after all. This year 
the program subcommittee had tried 
hard to cater for a diversity of interest. 
On Day 1 the four speakers gave 
the audience a sample of innovative 
services from different countries, ranging 
from how the pharmacists successfully 
engaged the government in Singapore, 
the pioneering Emergency Room (ER) 
pharmacist service in Australia, the 
comprehensive pharmacy development 
in Mainland China, to our own 
pharmacist’s initiatives in helping old age 
homes locally. The speeches were both 
informative and inspiring.
 The program on Day 2 was literally 
dazzling. Many felt sorry that they could 
not hear them all. The therapeutic 
debates were a new endeavor in Hong 
Kong. Both the audience and the 
speakers themselves found it full of fun 
and flare. Among the nine experts on the 
stage, they have left no stones unturned 
with the given therapeutic topics. The 
Pediatric series surely quenched the 
thirst of those interested in clinical 
pharmacy. The topics were well selected, 
and so were the speakers. 
 For those who were interested 
in technology and pharmacy 
operation, the sessions on medication 
reconciliation, e-Drug Management, 
unit dose dispensing, and decentralized 
automated system, really opened the 
eyes of the audience. The lectures on 
How to Improve Professional Image, and 
Leadership Lessons were suitable for 
both the young and the old.
 For those who would like to venture 
out into new services, they have 
found their interest in the new model 
for pharmacist’s service in China, 
collaboration between Pharmacist and 
Dietitian, the contribution of equine 
hospital pharmacist, case workshop 
from an ER Pharmacist, advanced 
primary care service. And to wrap 
everything up, the workshop on how 
to plan for a new service has been 
meaningful.
 Lastly, but not the least, the plenary 
session on pharmacy manpower turned 
out to be a great success. Although 
there were no concrete figures coming 
out on manpower projection for the 
whole of Hong Kong, the audience were 
all captivated and deeply moved by the 
positive and hearty inspiration of the 
panel and the moderator. It has aptly 
brought the Conference to a close under 
a very emotional atmosphere.
The Site Preparation and Performance
People outside of the Organizing 
Committee (OC) may not be able to 
imagine the among of work involved in 
preparing the non-educational part of 
the Conference, but certainly we cannot 
express our appreciation ever enough 
to the site team, the opening and dinner 
performance teams, the game and lucky 
draw teams, and all their helpers. The 
opening video and the butterfly were 
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Honourable Guest Dr. KO, Wing Man
Poster Presentation
Hong Kong PharmaCare Orchestra (HKPCO)Opening Ceremony
Guests were watching the Musical - Pharmtom 
of the Opera-Action
Workshop conducted by Dr. TAYLOR, SimoneChairman Mr LING, Michael
Dancers on the stage
beautifully done. It gave the Conference 
a good start. Many were glad that the 
lucky draw was thrilling, especially when 
the grand prizes were given out. At least 
everyone went home with something to 
show their families how fun it was to go to 
the Conference Dinner this year.
 When we first contemplated a 
musical drama for the Silver Anniversary 
Conference, some might have doubts. 
We worried that busy pharmacists like 
yourselves may have to work very hard 
to put up a great show, and we know 
your drama and music directors and 
producers would not settle for anything 
less than a grand performance. And 
our worries were proven to be founded! 
Indeed you all have been working double, 
triple hard in planning, practicing and 
rehearsing for the show. It ached inside 
me to see some of you looked tired, 
emaciated, and on the verge of being ill. 
Paradoxically, despite the exhaustion, 
you all looked happy and highly 
energized. In the end the performance 
was so overwhelming that the audience 
[Photos of the Conference are kindly presented and provided by Mr LAU, Michael.]
felt silent when the sad songs were 
sung, and excited when the scene was 
motivating. The loud applause at the 
end of musical swept away all our earlier 
doubts that the audience may not be 
engaged. 
 The site managers did a wonderful 
job. Given that their task is to put every 
bit and piece of the Conference together, 
and to entertain requests from different 
organizing teams, speakers and guests, 
they had to be performing many little 
miracles that the flow of the Conference 
was so flawless.  
The nuts and bolts, the cogs and wheels
A great team can never be great without 
a bunch of backend workers who 
paddle like ducks silently without people 
noticing them. Our conference secretary, 
finance manager, treasurer, public 
relation officers, gimmick coordinator, 
registration and IT, photographers, 
our MCs and helpers, you are all the 
nuts and bolts, the cogs and wheels of 
the entire operation. Without you all, 
everything will fall apart.
 When we first started the planning 
process of the Conference, we met with 
some operational challenges. Even 
towards the end of the preparation work, 
there were many last minute hiccups. 
Like one of you often said, “The show 
must go wrong, but the show must go 
on!” Yes, the show had gone on, and the 
outcome was marvelous. Like I said in my 
opening address, I hope this experience of 
so many people coming together to build 
such a great conference will not dissipate 
afterwards, but will meet together in the 
future to face the challenges we may 
encounter at work, for the sake of our 
patients and our profession! 
 See you all again in the next 
Conference Organizing Committee!    
Michael LING
Chairman
Hong Kong Pharmacy Conference 2013 
– Silver Jubilee
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Each fi lm-coated tablet 
contains 90 mg ticagrelor.
Pharmacological Properties:
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Ticagrelor, co-administered 
with acetylsalicylic acid (ASA), 
is indicated for the prevention 
of atherothrombotic events 
in adult patients with 
Acute Coronary Syndromes 
(unstable angina, non ST 
elevation Myocardial Infarction 
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Drug Interactions:
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Side Effects:
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Hong Kong Pharmaceutical Journal:
For Detailed Instructions for Authors
INTRODUCTION
Hong Kong Pharmaceutical Journal 
(HKPJ) is the official publication of the 
Pharmaceutical Society of Hong Kong, 
the Practising Pharmacists Association 
of Hong Kong and the Society of Hospital 
Pharmacists of Hong Kong. It is a journal 
of the pharmacists, for the pharmacists 
and by the pharmacists. The Journal is 
currently divided into several sections: 
Editorial Comment; News & Short 
Communications; Pharmacy Practice; 
Over-the-Counter & Health; Drugs 
& Therapeutics; Herbal Medicines 
& Nutraceuticals; Pharmaceutical 
Technology and New Products. It 
publishes review articles or original 
papers relevant to these different fields 
of pharmacy. In addition to the regular 
four issues of the Journal per year, there 
are issues dedicated solely to reports on 
special function of the society. The Aims 
and Scope of the Journal are published 
on the inside back cover of each issue.
Submission of Manuscript
Submission of a paper implies that it has 
not been published previously, that it is 
not under consideration for publication 
elsewhere, and that if accepted it will 
not be published elsewhere in the 
same form, in English or in any other 
language, without the written consent 
of the publisher. Authors are specifically 
discouraged from submitting papers as 
fragmented studies of a particular topic. 
A manuscript must be indicated which 
section it is belonged. Upon received, it 
will be screened by a Sectional Editor 
of HKPJ for initial consideration before it 
is sent out for further review or comment.
For online submission:
Authors are encouraged to submit 
manuscripts using the online submission 
system. Access to the system, and full 
instructions on its use, can be found on 
the HKPS website at: http://www.HKPS.
org/HKPJ/Guidelines. In creating the 
electronic version of their manuscript, 
authors are requested to follow the 
guidelines for submitting files. The paper 
should be submitted as a single file, 
prepared with a standard word-processor 
such as Microsoft Word, with embedded 
tables and graphics. Please note that 
any embedded graphics must also be 
submitted as separate, original files. 
The preferred formats for graphics files 
are tiff or postscript. All correspondence 
between Editor and author is performed 
by email.  Authors are reminded that 
the copyright of their article or paper is 
automatically transferred to HKPJ once it 
is accepted for publication in the journal. 
For hardcopy submission:
Three copies of the manuscript are 
required on either 8.5”x11” or A4 paper 
(two copies are used for review purposes 
and the original is kept on file at the 
Section Editor). Copies must be produced 
on a high-quality printer, and originals and 
copies of all Figures and Schemes must be 
fully legible. Initially only send hard copies 
of the paper; when it has been refereed, 
revised if necessary, and accepted, you 
will be requested to send a disk containing 
the final version with the final hard copy 
to the appropriate Editor. Make sure that 
the disk and the hard copy match exactly. 
The revised manuscript must be returned 
to the Editors within one month, otherwise 
it may be deemed to be new and subject 
to further review. When submitting the 
final version with a disk please label all 
disks with “HKPJ”, your name, software 
(e.g. word 2000), hardware used (e.g. 
PC or Macintosh) and file names with the 
correct extension (e.g. Fig 1.cdx, Table 1-6.
xls). Save text on a separate disk from the 
graphics, include the text and tables in one 
file, and provide graphics and structures 
in separate numbered files. Please 
remember to keep a backup copy of both 
the electronic files and original manuscript 
for reference and safety since we cannot 
accept responsibility for damage or loss of 
papers. Original manuscripts are discarded 
three months after publication unless 
the Publisher is asked to return original 
material after use. 
Suggested Referees
Please submit, with your manuscript, 
the names and addresses of 2 potential 
referees. You may also mention persons 
who you would prefer not to review your 
paper.
Editorial Authority 
The Editors of HKPJ reserve the right to 
make alterations to manuscripts submitted 
for publication. Such alterations will be 
made if manuscripts do not conform with 
accepted scientific standards or if they 
contain matter which in the opinion of 
the Editors is unnecessarily verbose or 
unclear. Alterations may be queried, but 
this will inevitably delay publication.
Preparation of manuscript
The manuscript is required to be written 
in English, with numbered pages, single-
spaced, using Arial 9 point font, and in a 
suitable word-processing format. Each 
page should have adequate margins (4 
cm) and liberal spaces at top and bottom of 
the manuscript. All textual elements should 
begin flush left, with the second paragraphs 
onwards indent, and should use the wrap-
around end-of-line feature, i.e. no returns 
at the end of each line. Place two returns 
after every element such as title, headings, 
paragraphs, figure and table call-outs. 
Most formatting codes will be removed or 
replaced on processing your article. Please 
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breaking, justified layout, double columns or 
automatic paragraph numbering (especially 
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bold face, italic, subscripts, superscripts 
etc. The Editors reserve the right to adjust 
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authors are unfamiliar with HKPJ, they 
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online sample copy available from www.
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currently followed for guidance in preparing 
submissions. 
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authors name(s) and address(es); (2) 
an Abstract, in which contents are briefly 
stated; (3) a 4 to 6 Key Word Index, (4) 
Introduction, and (5) the Results and 
Discussion (preferably combined). Although 
each section may be separated by 
headings, they should form one continuous 
narrative and only include details essential 
to the arguments presented. If a discussion 
is separately provided, it should not include 
a repetition of the results, but only indicate 
conclusions reached on the basis of them, 
and those from other referred works; (6) 
Conclusions or Concluding Remarks; (7) 
the Experimental should include brief details 
of the methods used such that a competent 
researcher in the field may be able to 
repeat the work; (8) Acknowledgments; 
(9) References; (10) Legends, Formulae, 
Tables and Figures. 
Title Page and Author Names: Titles must 
be as brief as possible, consistent with 
clarity, and should not exceed 10 words 
in length. Uninformative phrases such as 
“Chemical examination of”, “Studies 
on”, “Survey of”, “New”, “Novel” etc. will 
be deleted. If a paper is part of a series, 
this must not be given in the heading, but 
referred to in a footnote in the form: *Part 
9 in the series “The Role of Pharmacists 
in Medical Care of Patients” followed by 
a numbered reference to the previous 
part. Author names should be typed right 
underneath the article title. Each author 
should identify himself or herself with 
Surname in capital letters, followed by the 
first name. All names are separated by a 
semicolon ( ; ). An asterisk should be placed 
following the name of the author to whom 
correspondence inquiries should be made. 
Full postal addresses must be given for 
all co-authors. Superscript letters; a, b, c 
should be used to identify authors located at 
different addresses. 
 An Author’s background box at the 
end of each article is mandatory to include 
the author’s job title and the affiliated 
institutle or organization. Full details 
of telephone, fax numbers and e-mail 
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address should also be indicated for the 
corresponding authors. No academic or 
professional membership title is allowed.
ABSTRACT: The abstract should be on 
a separate page and briefly describe the 
results obtained and conclusions reached, 
not the methods used, or speculations on 
any other matter. They are not expected 
to be a complete summary but only an 
outline of the main findings. The abstract 
should be contained within 250 words and 
should be readable without reference to 
the rest of the paper.
Key Words: Authors must give four to 
six “key words” or phrases, which identify 
the most important subjects covered by 
the paper. 
INTRODUCTION should give the 
minimum historical data needed to 
give appropriate context to the author’s 
investigation and its relationship to other 
similar research previously or currently 
being conducted. Only information 
essential to the arguments should be 
presented. Much data can be taken for 
granted or quoted in abbreviated form. 
Specific term (genus, species, authority) 
of all experimental works must be given 
at first mention and preferably be in 
the form adopted by the International 
Scientific Community. 
RESULTS AND DISCUSSION: These 
sections should be carefully prepared 
with discussions of the results being 
compared with existing and/or previous 
knowledge within the field. Authors 
are, however, encouraged to combine 
the Results and Discussion sections 
wherever possible.
EXPERIMENTAL: Subsections on the 
Experimental Procedures should be 
italicized and inserted as part of the 
first line of the text to which they apply. 
HKPJ encourages an extensive use of 
abbreviations (these are listed at the back of 
the Instructions to Authors, or the reader is 
referred to other sources). The Experimental 
should begin with a subsection entitled 
General Experimental Procedures. This 
subsection will typically contain brief details 
of instruments used, and identification 
of sources of specialized chemicals, 
biochemicals and molecular biology kits. 
The next subsection describes the source(s) 
and documentation of biological materials 
used, whether in reference to whole plants 
or parts there from, crude drugs, or any 
other plant material from which identifiable 
chemical substances are obtained for the 
first time. Documentation must also include 
a reference to voucher specimen(s) and 
voucher number(s) of the compounds, 
plants or other material examined. If 
available, authors should quote the name 
and address of the authority who identified 
each sample investigated. Specimens 
should preferentially be deposited in a major 
regional herbarium where the collection is 
maintained by state or private institution and 
which permits loan of such materials. With 
other microorganisms, the culture collection 
from which they were either accessed and/
or deposited should be included, together 
with identification of the strain designation 
code. The Experimental Procedures 
employed should be concise but sufficiently 
detailed that a qualified researcher will be 
able to repeat the studies undertaken, and 
these should emphasize either truly new 
procedures or essential modifications of 
existing procedures. Experimental details 
normally omitted include: (I) method of 
preparation of common chemical and 
biochemical derivatives, (2) excessive 
details of separation of compounds, 
proteins and enzymes, e.g. preparation of 
columns, TLC plates, column and fraction 
size. Compound Characterization: Physical 
and spectroscopic data for new compounds 
must be comprehensive, and follow the 
order shown below: compound name (and 
assigned number in text); physical state 
of compound (e.g. oil, crystal, liquid, etc.), 
melting and/or boiling point; optical rotation 
and/or circular dichroism measurements, 
if optically active; UV; JR, lH NMR; 13C 
NMR; MS. For all new compounds, either 
high-resolution mass spectral or elemental 
analysis data is required. See later section 
for method of data presentation.
Nomenclature: Chemical nomenclature, 
abbreviations and symbols must follow 
IUPAC rules. Whenever possible, avoid 
coining new trivial names; every effort 
should be made to modify an existing 
name. For example, when a new 
compound is described, it should be given 
a full systematic name according to IUPAC 
nomenclature and this should be cited in the 
Abstract or in the Experimental section. 
ACKNOWLEDGMENTS: This section 
is used to provide brief credit for 
scientific and technical assistance, 
and in recognition of sponsorship 
through financial support and any other 
appropriate form of recognition.
References: All publications cited in 
the text should be presented in a list 
of references following the text of the 
manuscript. In the text refer to the 
author’s name (without initials) and year 
of publication (e.g. “Since Peterson 
(1993) has shown that ...” or “This is in 
agreement with results obtained later by 
Kramer.(4)” For two authors both authors 
are to be listed, with “and” separating the 
two authors. For more than two authors, 
use the first author’s surname followed 
by et al. The list of references should be 
arranged according to the order of their 
appearance in the text with no more than 
three authors listed. If number of authors 
of a reference exceeds three, “et al” is 
used followed by year of publication 
in bracket after the first author. Journal 
titles should be completely shown 
followed by the volume, issue number 
in bracket if included, colon and start 
– final page number. The manuscript 
should be carefully checked to ensure 
that the spelling of authors’ names and 
dates are exactly the same in the text as 
in the reference list. Some examples of 
references are shown below:
 (1) Cabello-Hurtado F, Durst F, Jorrin 
JV, Werck-Reichhart D. et al. (1998). 
Coumarins in Helianthus tuberosus: 
characterization, induced 
accumulation and biosynthesis. 
Biochemistry, 49(1):1029-1036.
 
 (2) Mabry T, Markham KR, Thomas MB. 
(1970). The Systematic Identification 
of Flavonoids. 2nd Ed, pp. 79-105. 
Springer Verlag, New York.
 (3) Harborne JB. (1999). Plant chemical 
ecology. In: Barton D, Nakanishi K, 
Meth-Cohn 0, (Eds.), Comprehensive 
Natural Products Chemistry, Vol. 8. 
pp. 137-196. Pergamon, Oxford.
Preparation of Illustrations: All illustrations 
should be provided in camera-ready form, 
suitable for reproduction (which may include 
reduction) without retouching. Illustrations 
(figures, tables, etc.) should be prepared 
for either single or double column format. 
For online submission illustrations should 
be included in the manuscript and also be 
submitted separately as high resolution 
files. For hardcopy submission illustrations 
should be submitted on separate pages 
in camera-ready format with legends on 
separate pages. Hardcopy illustrations 
supplied by authors are digitally scanned 
into the appropriate page and must therefore 
be of the highest quality. Where possible 
the original electronic files are used, figures 
produced by computer must therefore be 
prepared at a minimum resolution of 300 
dpi. Refer to all photographs, charts and 
diagrams as “Figure(s)” and number them 
consecutively in the order to which they 
are referred. They should accompany the 
manuscript, but should not be included 
within the text. All illustrations should be 
clearly marked with the figure number 
and the author’s name (either on the back 
if submitting on paper or with a clear file 
name if submitting online). All figures are to 
have a caption, which should be supplied 
on a separate page. Note: Illustrations 
of the following type generally will not be 
accepted for publication: (1) diagrams 
or photographs of chromatograms (PC 
and TLC), electrophoretic separations, or 
recorder traces of GC and HPLC data which 
are given merely to prove identification; (2) 
straight-line graphs; (3) generalized pH 
and temperature-denaturation curves of 
enzymes; (4) illustrations of IR, UV, NMR 
or MS (values can be quoted in the text or 
Experimental); (5) flow sheets illustrating 
isolation of compounds; (6) expectable MS 
fragmentation patterns; (7) formulae of well-
known compounds or reaction schem~s; 
(8) tables giving either single values for 
each parameter which could be easily 
quoted in the text, or repeating data shown 
elsewhere.
 Illustrations should be drawn on separate 
pages and prepared with good contrast 
(black on a white background). Lettering 
in tables, figures, etc: lettering in formulae, 
figure axes etc. must be large enough to 
be legible after reduction. Lettering should 
be drawn in 6-7pt Helvetica (Arial) font 
to ensure optimum visibility. Chemical 
formulae must be made absolutely clear; 
printers are not chemists and much delay 
is caused by poor drawing. Aromatic rings 
must be drawn with alternate double bonds 
and conformation of single bonds shown by 
thickened or dashed (III) lines according to 
convention. Formulae should be numbered 
consecutively in Arabic numerals. If 
graphics are created using ChemDraw or 
ISISDraw the preferred settings are: font 
10 pt Helvetica (Arial), chain angle 120o 
HKPJ   VOL 20  NO 1   Jan-Mar 2013
50
HKPJ   VOL 20  NO 1   Jan-Mar 2013
51
bond spacing 18% of length, fixed (bond) 
length 14.4 pt (0.508 cm), bold width (bond 
thickness) 2.0 pt (0.071 cm), line width 0.6 
pt (0.021 cm), margin width 1.6 pt (0.056 
cm), and hash spacing 2.5 pt (0.088 cm). 
The overall size should be not more than 
95mm (single column) or 194mm (double 
column) by 285 mm.
 Tables must be typed on separate 
pages, numbered consecutively, given a 
suitable caption and arranged to be viewed 
vertically. They must be so constructed 
as to be intelligible without reference to 
the text. Every table must have an Arabic 
number and a title, and each column must 
be provided with an explanatory heading. 
No vertical rules should be used. Tables 
should not duplicate results presented 
elsewhere in the manuscript (e.g. in graphs). 
Footnotes may be used to expand column 
headings, etc. and should be referenced by 
superscript lowercase letters a,b,c rather 
than symbols. Results should be cited 
only to the degree of accuracy justified on 
the basis of the errors of the method and 
usually only to three significant figures. 
Units must always be clearly indicated and 
chosen so as to avoid excessively high 
(>100) or low (<0.01) values. The figure 
zero should precede the decimal point for 
all numbers below one (e.g. 0.1). 
 Half-tone photographs must have 
good contrast and not be more than 25 
cm wide and not more than 30 cm high. 
Original photographs (or high resolution 
graphic files of at least 500 dpi) must be 
supplied as they are to be reproduced (e.g. 
black and white or colour). If necessary, 
a scale should be marked on the 
photograph. Please note that photocopies 
of photographs are not acceptable. 
Colour charges
Authors are encouraged to submit their 
works in colour. There is no charge for 
colour print.
Supplementary data 
HKPJ now accepts electronic 
supplementary material to support 
and enhance your scientific research. 
Supplementary files offer the author 
additional possibilities to publish 
supporting applications, movies, 
animation sequences, high-resolution 
images, background datasets, sound 
clips and more. Supplementary files 
supplied will, subject to peer review, be 
published online alongside the electronic 
version of your article in HKPS website. 
The presence of these files will be 
signified by a footnote to the article 
title, and by a description included in a 
‘Supplementary Data’ section at the end 
of the paper. In order to ensure that your 
submitted material is directly usable, 
please ensure that data is provided in 
one of our recommended file formats 
and supply a concise and descriptive 
caption for each file. Please also clearly 
indicate whether data files are either i) for 
publication online or ii) only to be used as 
an aid for the refereeing of the paper. For 
more detailed instructions please visit our 
Author Gateway at htto://authors.HKPJ.org
 Errata and Corrigenda to publish 
articles will be included, at the discretion 
of the Section Editors and the publisher.
Abbreviations
About, approximately: ca.
Anhydrous: dry (not anhyd.)
Aqueous: aq.
Circular dichroism: CD
Concentrated (or mineral acids): conc.
Concentrations: ppm (or ppb), µM, mM, 
M, %, mol
Dry weight: dry wt; fresh weight: fr. wt
Electricity: V, mA, eV
Force due to gravity (centrifugation): g; 
rpm (revolutions min-1)
Gas chromatography: GC
Gas chromatography-mass spectrometry: 
GC-MS Trimethylsilyl derivative: TMSi 
(TMS cannot be used as this refers to the 
internal standard tetramethylsilane used 
in 1H NMR)
High performance liquid chromatography: 
HPLC
Infrared spectrophotometry: IR
Length: nm, µm, mm, cm, m
Literature: lit.
Mass spectrometry: m/z [M]+ (molecular 
ion, parent ion)
Melting points: uncorr. (uncorrected)
Molecular mass: Da (daltons), kDa
Molecular weight: Mr
Nuclear magnetic resonance: 1H NMR, 
13C NMR, Hz, δ
Numbers: e.g. 1, 10, 100, 1000, 10000; 
per or -1
Optical rotatory dispersion: ORD
Paper chromatography: PC
Precipitate: ppt.
Preparative thin-layer chromatography: 
prep. TLC
Radioactivity: dpm (disintegrations 
per min), Ci (Curie), sp. act (specific 
activity), Bq (1 becquerel = 1 nuclear 
transformation sec-1)
Repetitive manipulations: once, twice, 
x3, x4, etc.
RRt (relative retention time), R1 (Kovat’s 
retention index), ECL (equivalent chain 
length- term frequently used in fatty acid 
work)
Saturated: satd.
Solution: soln.
S o l v e n t  m i x t u r e s  i n c l u d i n g 
chromatographic solvents: abbreviate 
as follows n-BuOH-HOAc-H2O (4:1:5)
Statistics: LSD (least significant 
difference), s.d. (standard deviation), s.e. 
(standard error)
Temperature: (with centigrade), mp, mps, 
mmp, bp
Temperature: temp.
Thin-layer chromatography: TLC, Rf
Time: s, min, h, day, week, month, year
Ultraviolet spectrophotometry: UV, A 
(absorbance, not aD-optical density)
Volume: 1, (litre), µ1, ml
Weight: wt, pg, ng, µg, mg, g, kg
 Inorganics, e.g. AICl3 (aluminum 
chloride), BF3 (boron trifluoride), Cl., CO3, 
H2, HCl, HCIO4 (perchloric acid), HNO3. 
H2O, H2O2, H2SO4, H3B03 (boric acid), He, 
KHCO3 (potassium bicarbonate), KMn04 
(potassium permanganate;), KOH, K-Pi 
buffer (potassium phosphate buffer), 
LiAIH4 (lithium aluminium hydride), Mg2+, 
MgCI2, N2, NH3, (NH4)2S04, Na+, NaBH4 
(sodium borohydride), NaCl, Nal04 (sodium 
periodate), NaOH, Na2S03 (sodium sulphite), 
Na2S04 (sodium sulphate), Na2S203 (sodium 
thiosulphate), 03, PPi (inorganic phosphate), 
SO42−., Tris (buffer).
 Organics, e.g. Ac20 (acetic anhydride), 
n-BuOH (butanol), C6H6 (benzene), CCl4 
(carbon tetrachloride), CH2Cl2 (methylene 
chloride), CHCl3 (chloroform), CH2N2 
(diazo-methane), CM (carboxymethyl), 
DEAE (diethylaminoethyl), DMF 
(dimethylformamide), DMSO (dimethyl 
sulphoxide), EDTA (ethylene-diaminetetra-
acetic acid), Et20 (diethyl ether), EtOAc 
(ethyl acetate), EtOH (ethanol), HC02H 
(formic acid), HOAc (acetic acid), iso-PrOH 
(iso-propanol), Me2CO (acetone), MeCOEt 
(methyl ethyl ketone), MeOH (methanol), 
NaOAc (sodium acetate), NaOMe (sodium 
methoxide), petrol (not light-petroleum or 
petroleum ether), PhOH (phenol), PrOH 
(propanol), PVP (polyvinylpyrrolidone), 
TCA (trichloroacetic acid), TFA 
(trifluoroacetic acid), THF (tetrahydrofuran). 
1H NMR solvents and standards: CDCl3 
(deutero-chloroform), D2O, DMSO-d6 
[deuterodimethylsulphoxide not (CD3)2S0], 
pyridine-d5 (deuteropyridine), TMS 
(tetramethylsilane).
 For further terms used in biochemistry 
and molecular biology the authors should 
see the websites of the nomenclature 
committees (www.chem.qmul.ac.uk/iubmb/).
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There is no page charges for HKPJ.
Proofs and Articles in Press
Proofs will be despatched via e-mail to the 
corresponding author, by the Publisher 
and should be returned with corrections 
as quickly as possible, normally within 48 
hours of receipt. Proofreading is solely 
the author’s responsibility. Authors should 
ensure that corrections are returned in 
one communication and are complete, 
as subsequent corrections will not be 
possible. Any amendments will be 
incorporated and the final article will then 
be published online as an Article in Press.
Offprints
Two copies containing the offprints will 
be supplied free of charge. Additional 
offprints and copies of the issue can be 
ordered at a specially reduced rate using 
the order form sent to the corresponding 
author after the manuscript has been 
accepted. Late orders for reprints will 
incur a 50% surcharge.
Copyright
Upon acceptance of an article, Authors 
will be assumed to transfer copyright 
unconditionally to HKPJ. This transfer will 
ensure the widest possible dissemination 
of information. If excerpts from other 
copyrighted works are included, the 
Author(s) must obtain written permission 
from the copyright owners and credit the 
source(s) in the article. 
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